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Targeting the Epigenetic Lesion in MLL-rearranged Leukemia 
Abstract 
 
It has become increasingly apparent that the misregulation of histone modification actively contributes to 
cancer.  The  histone  H3  lysine  79  (H3K79)  methyltransferase  Dot1l  has  been  implicated  in  the 
development  of  leukemias  bearing  translocations  of  the  Mixed  Lineage  Leukemia  (MLL)  gene.    We 
studied the global epigenetic profile for H3K79 dimethylation and found abnormal H3K79 dimethylation 
profiles exist not only in leukemias driven by MLL-fusion proteins with nuclear partners like AF9, but 
also in leukemia with MLL-fusions containing cytoplasmic partners like AF6. Genetic inactivation of 
Dot1l  led  to  downregulation  of  fusion  target  genes  and  impaired  both  in  vitro  bone  marrow 
transformation and in vivo leukemia development by MLL-AF10, CALM-AF10 as well as MLL-AF6, 
suggesting that aberrant H3K79 methylation by DOT1L sustains fusion-target gene expression in MLL 
rearranged  leukemias  and  CALM-AF10  rearranged  leukemias.  Pharmacological  inhibition  of  DOT1L 
selectively killed MLL-AF10 and MLL-AF6 transformed cells but not Hox9/Meis1 transformed cells, 
pointing to DOT1L as a potential therapeutic target in MLL-rearranged leukemia.  
 
We further characterized the DOT1L complex under physiological conditions from human leukemia cells 
and identified AF10 as a key DOT1L complex component. Given the importance of H3K79 methylation 
in MLL-rearranged leukemia, we sought to study the role of DOT1L complex component AF10 in H3K79 
methylation and MLL leukemia. We generated conditional knockout mice in which the Dot1l-interacting 
octapeptide-motif  leucine-zipper  (OM-LZ)  domain  of  Af10  was  flanked  by  LoxP  sites.  Cre  induced 
deletion of Af10
OM-LZ is predicted to abrogate the Af10-Dot1l interaction. Our histone mass spectrometry  
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data  demonstrated  that  deletion  of  the  endogenous  Af10
OM-LZ  domain  abrogated  global  H3K79 
dimethylation but retained H3K79 monomethylation. Interestingly, bone marrow transformation by MLL-
AF6  and  MLL-AF9  is  abrogated  by  induced  deletion  of  endogenous  Af10
OM-LZ,  while  bone  marrow 
transformation by MLL-AF10 and CALM-AF10 is not affected by deletion of endogenous Af10
OM-LZ, 
confirming the importance of Af10-Dot1l interaction in MLL- or CALM fusion-leukemias. Moreover, we 
showed  Af10
OM-LZ  deletion  prolonged  survival  of  MLL-AF9  leukemia  in  vivo  and  led  to  chromotin 
compaction and downregulation of MLL fusion targets in MLL-AF9 leukemia. Therefore our results 
demonstrate a role for Af10 in the conversion of H3K79 monomethylation to dimethylation and reveal the 
AF10-DOT1L interaction as an attractive therapeutic target in MLL-rearranged leukemias. 
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Introduction 
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Characteristics of MLL-rearranged Leukemia 
 
Chromosomal  translocations  which  encode  fusion  proteins  are  frequently  associated  with  human 
leukemias. Current advances in biology, biochemistry and pharmacology have raised the prospects of 
highly  targeted  leukemia  therapeutics  that  maximize  efficacy  and  minimize  systemic  toxicity.  One 
outstanding example is targeting the fusion protein BCR-ABL kinase by imatinib in chronic myeloid 
leukemia  (1).  In  our  lab,  we  focus  on  studying  leukemia  bearing  translocation  involving  the  Mixed 
Lineage Leukemia (MLL) gene on chromosome band 11q23. MLL-rearranged leukemia is a subset of 
leukemia with distinct biological and clinical characteristics (2). Despite the advances in treatments in 
other leukemias, leukemias bearing MLL rearrangement are still associated with a very poor prognosis.  
   
Translocations involving the MLL gene are present in about 10% of all human leukemias, but over 70% of 
infant leukemias (3, 4). Since its first identification in 1991, MLL gene has been identified by molecular 
studies to be recurrently fused with a diverse array of partner genes in acute lymphoblastic leukemia 
(ALL), acute myeloid leukemia (AML), biphenotypic or acute mixed-lineage leukemias, and secondary 
leukemia after chemotherapy with Topoisomerase II inhibitors (5). Whereas children with acute leukemia 
that does not harbor a MLL translocation have an overall survival of >80%, infants diagnosed with MLL-
rearranged leukemia fail to benefit from intensive chemotherapy, radiation therapy or allogeneic stem cell 
transplantation, and have an overall survival of 30-50% (6, 7). Thus new therapeutic approaches are 
clearly needed for patients with MLL-rearranged hematopoietic malignancies. 
 
Although the oncogenic property of MLL fusion proteins has been proven by several retroviral models (8, 
9) and MLL fusion knock-in mouse models (10-12), the underlying mechanisms of leukemogenesis is yet 
unknown.  Wildtype  MLL  is  a  mammalian  homolog  of  the  Drosophila  Trithorax  protein,  and  it  has 
multiple functional domains including the N terminal AT hoods that bind to DNA and the C terminal 
Suv39, Enhancer of Zeste, Trithorax (SET) domain that methylates histone H3 lysine 4 (13). In mammals,  
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MLL maintains the expression pattern of Homeobox (HOX) genes during development, and is essential 
for hematopoiesis (14). Mll knockout mice show the expression of stage-specific Hox genes is initiated 
but not maintained in the absence of Mll. As a result of MLL translocations, the N terminus of MLL fuses 
with the C terminus of more than 60 different partner proteins, among which AF4, AF9, ENL, AF10, AF6, 
ELL, AF1P, AF17 and SEPT6 are the most common (5). There are three main functional categories for 
MLL  fusion  partners.  One  category  of  fusion  partners  normally  coexist  in  a  P-TEFb  containing 
transcriptional elongation complex or a histone methyltransferase Dot1l-containing complex (DotCom) 
(15) in the nucleus. Many MLL fusion partners, such as AF10, ENL, ELL, AF9, AF4 and AF5q31, have 
been  identified  in  either  DotCom  or  transcriptional  elongation  complexes  called  AF4,  ENL,  P-TEFb 
Complex (AEP) (16) or Super Elongation Complex (SEC) (17). It is thought that the MLL fusion protein 
recruits DOT1L or AEP/SEC to promote RNA polymerase II-mediated transcription of MLL target genes. 
The second category of fusion partners are cytoplasmic proteins important in various functions such as 
cellular adhesion, endocytosis, cytoskeleton organization, and signal transduction. This category includes 
coiled-coil domain-containing proteins such as AF6, AF1q, GAS7, EEN, and the SEPTIN family. The 
common feature of these cytoplasmic proteins is their ability to self-associate via the coiled-coil domains 
(18). It is noteworthy that these oligomerization domains are necessary and sufficient for MLL fusion 
mediated transformation and even MLL artificial homodimer can immortalize hematopoietic cells (18). 
The  third  category  of  MLL  fusion  partners  includes  transcriptional  factors,  such  as  forkhead  family 
members AFX (19) and chromatin remodeling factors, such as histone acetyltransferase CBP and p300 
(20, 21). These proteins are important for the recruitment of RNA polymerase II and the initiation of 
MLL target gene transcription in their respective fusion events.   
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Figure 1-1 Distribution of major MLL fusion partner genes in de novo childhood and adult leukaemias.  
Adapted from review (2). AF4 is predominantly found in ALL and AF9 and AF10 are predominantly found in AML.  
 
Despite the remarkably diverse MLL fusion partners, all the MLL-rearranged leukemias share a similar 
and  distinct  leukemogenic  gene  expression  program,  with  aberrant  activation  of  MLL  target  genes 
including HOXA cluster genes and MEIS1 (2, 22). HOX genes are transcription factors that participate in 
the  development  of  multiple  organs  and  hematopoiesis.  HOXA  cluster  genes  are  normally  highly 
expressed only in early hematopoietic progenitors (23). Wildtype MLL can maintain the expression of 
HOXA cluster genes in early hematopoietic progenitors but also allow the down-regulation during normal 
development. However MLL fusion partners constitutively drive the expression of HOX genes. Strikingly, 
when ectopically expressed together, HOXA9 and MEIS1 can transform hematopoietic cells in vitro and 
induce leukemia in retrovial mouse models that recapitulate human MLL-rearranged leukemia (24). How 
a heterogeneous group of partner proteins leads to similar leukemia features in MLL-rearranged leukemia 
is still unclear. It is believed that MLL fusion event disrupt the normal function and gain new functions 
from wild-type MLL and its fusion partners. This is supported by functional studies of the minimal fusion 
that can transform hematopoietic cells, and clinical observation that all the MLL fusion proteins retained 
the open reading frame of the fusion partners, both implying the importance of fusion partner in the 
leukemogenesis. It is easy to understand that MLL fusion partners that reside in the nucleus recruit Pol II 
to the promoter regions or release Pol II from stalling at the transcriptional start sites. But it is less clear  
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why MLL fusion with cytoplasmic fusion partners that do not have transcriptional activation function and 
MLL N-terminal artificial homodimer can transform hematopoietic cells. Another hypothesis is that the 
homodimerization of MLL creates new domains with which the transcriptional elongation complexes or 
transcriptional coactivators interact. It was shown that MLL-AF6 does not recruit AEP/SEC or DOT1L 
complex, so this hypothesis still waits to be tested with more detailed biochemical studies.   
 
Recently, we and others have demonstrated another unique characteristic of MLL-rearranged leukemia- 
the genome-wide epigenetic lesion formed by histone H3 lysine 79 (H3K79) methyltransferase  Disruptor 
of telomeric silencing 1-like (DOT1L) (12, 16, 25). MLL-rearranged leukemia is a perfect example of 
how genetic corruption and epigenetic corruption cooperate together to initiate and maintain a disease. As 
discussed above, wildtype MLL is an epigenetic modifier with N-terminal DNA binding domains and C-
terminal H3K4 methyltransferase domain called SET domain. Methylation of H3K4 is usually associated 
with  positive  regulation  of  gene  expression.  Interestingly,  MLL  always  loses  its  SET  domain  after 
rearrangement  with  fusion  partners,  and  the  subtle  change  in  H3K4  methylation  profile  in  MLL-
rearranged leukemia would not be able to explain the global deregulation of gene expression in MLL-
rearranged leukemia. Through chromatin immunoprecipitation coupled with sequencing (ChIP-seq), our 
lab  studied  changes  of  different  epigenetic  marks  comparing  leukemia  stem  cells  and  the  common 
progenitors from which they arose, and found aberrantly high levels of H3K79 dimethylation across the 
gene bodies of MLL target genes only exist in leukemia stem cells but not in the common progenitors 
(12). H3K79 dimethylation is ubiquitously coupled with positive regulation of gene expression in normal 
cells but it is remarkably more enriched in MLL target genes than in other highly expressed genes in 
MLL-rearranged  leukemias  (25).  DOT1L  is  the  sole  enzyme  responsible  for  methylation  at  H3K79. 
Interestingly, several fusion partners of MLL, for example, AF9, ENL, AF4, and AF10, are shown to bind 
to DOT1L either directly or indirectly (26-29). However, DOTl is not a part of AEP/SEC in MLL fusion 
leukemias, and recent results indicate that AF9 or ENL cannot simultaneously bind P-TEFb and DOT1L. 
Moreover, MLL fusion partners that normally reside in the cytoplasm cannot directly recruit DOT1L to  
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MLL targets. Therefore, how DOT1L is recruited to MLL target genes in MLL-rearranged leukemia is 
still a mystery. 
 
Normal Hematopoiesis, Leukemogenesis, and Leukemia Cell of Origin 
 
Hematopoiesis  is  a  hierarchy  where  hematopoietic  stem  cells  (HSC)  possess  significant  self-renewal 
potential and their progeny cells with a restricted cell fate, have lost this potential. This developmental 
process is well-controlled by spacial and temporal expression of developmentally important genes, that 
are  turned  on  and  off  by  transcription  factors  and  perhaps  maintained  by  epigenetic  mechanisms. 
Definitive hematopoiesis starts with HSC, which have both the ability for unlimited self-renewal and the 
ability to differentiate into multipotent progenitors (MPPs). MPPs have limited self-renewal ability and 
can differentiate into common lymphoid progenitors (CLPs) and common myeloid progenitors (CMPs). 
CLP  can  ultimately  differentiate  into  B  and  T  cells  and  CMP  can  differentiate  into  granulocyte-
macrophage  progenitors  (GMP),  which  give  rise  to  various  granulocytes  and  macrophages,  and 
megakaryocyte-erythrocyte progenitors (MEP), which give rise to platelets and red blood cells.  
 
If in the journey of hematopoiesis, MLL rearrangement happens in hematopoietic stem cells or early 
hematopoietic progenitors, the mutant cells will have unlimited self-renewal potential, expand without 
differentiation, crowd out normal bone marrow cells and infiltrate into other organs, leading to clinical 
leukemia. MLL rearrangement breaks MLL in the breakpoint cluster region (BCR) region encompassing 
exons 5 through 11, where several topoisomerase II (topo II) cleavage sites, DNase I hypersensitive sites 
and scaffold attachment regions coexist and the free energy level for unwinding double strand DNA is 
very low (30). There is also a strong non-homologous end joining (NHEJ) repair signature including 
deletion, inversion and duplication in virtually all MLL rearrangement, suggesting MLL-rearrangement is 
caused by accidental cleavage of chromosomes and subsequent mistakes in NHEJ repair in hematopoietic 
cells (30).   
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Figure 1-2 MLL rearrangement in HSC and early progenitor cells leads to clinical leukemia. 
Adapted from review (2). 
 
 
Mouse  models  provide  an  extremely  useful  tool  for  understanding  the  mechanisms  of  MLL-fusion-
mediated  leukemogenesis  and  for  preclinical  development  of  rational  therapeutic  strategies.  Mll-AF9 
knock-in mouse models that constitutively express Mll-AF9 under wildtype MLL promoter, and Mll-Af9 
conditional knock-in mouse models that have Mll-Af9 interchromosomal translocation in hematopoietic 
cells both have a propensity of developing AML (10, 11). Conditional Mll-Enl knock-in mouse models 
have  rapid  onset  of  AML,  whereas  conditional  Mll-CBP  knock-in  model  results  in  myelomonocytic 
hyperplasia that can progress to a myeloproliferative or myelodysplastic disorder only after additional 
chemical  or  radiation-induced  mutagenesis  (20,  31).  These  knock-in  experiments  demonstrated  the  
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leukemogenic function of Mll fusions and also demonstrated that the N-terminal Mll knock-in alone is not 
leukemogenic in mice. As MLL-ENL and MLL-AF9 translocations are most frequently found in acute 
leukemias  and  MLL-CBP  translocation  is  most  frequently  found  in  myelodysplastic  syndrome  or 
therapeutics-induced acute leukemias, these mouse models appear to truly recapitulate the disease found 
in humans. Since MLL-AF4 is the most frequent translocation found in ALL patients, it would be useful 
to develop an Mll-Af4 mouse model that faithfully recapitulates human MLL-AF4 leukemia. However, 
initial  mouse  models  of  constitutive  Mll-AF4  knock-in  only  resulted  in  mixed  lymphoid/myeloid 
hyperplasia  and  mature  B-cell  neoplasms  in  mice  (32).  Conditional  expression  of  Mll-AF4  by 
interchromosomal  recombination  in  lymphoid-specific  cells  produced  mature  B-cell  lymphomas  but 
failed to cause any ALL (32). Nevertheless, a more recently developed conditional Mll-AF4 knock-in 
mouse model that specifically knock-in Mll-AF4 in hematopoietic stem cell and progenitors, developed 
ALL or AML with a median latency around 100 days, and the mouse Mll-AF4 leukemia cells share very 
similar global gene expression patterns and H3K79 methylation profiles with human MLL-AF4 leukemia 
cells  (12).  This  Mll-AF4  mouse  model  demonstrated  that  Mll-AF4  leukemia  have  a  distinct  gene 
expression pattern and a distinct H3K79me2 profile from MLL-wildtype leukemia cells. Interestingly, 
although MLL-fusion proteins are also expressed in other tissue like brain and kidney in the constitutive 
MLL-fusion knock-in mouse models, only hematopoietic related malignancies develop, suggesting that 
MLL-fusion proteins are only cancerous for the hematopoietic system. 
 
Besides  knock-in  mouse  models,  mouse  models  based  on  retroviral  gene  transfer  and  bone  marrow 
transplantation have also been a useful approach for understanding MLL fusion functions in leukemia 
development. In retroviral models, normal bone marrow cells are harvested from mice, transduced with a 
retrovirus carrying the MLL fusion gene and the cells are then analyzed in vitro or injected into syngenic 
mice to assess leukemia development in vivo. Using this approach, it has been shown that MLL-ENL and 
MLL-AF9 can induce acute leukemia from mouse bone marrow progenitors as well as human cord blood  
 
9 
 
progenitors (33, 34). Retroviral models also demonstrated that MLL-GAS7, MLL-AF9, and MOZ-TIF2, 
but not BCR-ABL can transform committed progenitors that have limited self-renewal potential as well as 
hematopoietic stem cells that have unlimited self-renewal potential (8, 35). When reprogrammed by MLL 
fusion genes, the committed progenitors can maintain the global identity of the progenitor from which 
they arose while activating a self-renewal associated program (8). This finding defines progression from 
normal progenitor to cancer stem cell and suggests that targeting a self-renewal program expressed in an 
abnormal context may be possible. 
 
Epigenetics and Cancer Therapy 
 
In eukaryotic cells, DNA is wrapped around a histone octamer comprised of one (H3/H4)2 heterotetramer 
and two H2A/H2B dimers to form the nucleosome, the fundamental building block of chromatin. Genetic 
information is stored in the genome sequence and it serves as a bank of information for all the cells in a 
multicellular eukaryotic organism. During normal development or disease progression, cells change their 
identities, express various sets of genes and function differently. Unlike genetics, epigenetics refers to all 
the heritable changes of cellular status that are not related to the change of DNA sequence. Epigenetics 
involves  DNA  methylation,  histone  modification  and  chromatin  remodeling  and  is  crucial  for  the 
establishment and maintenance of gene expression patterns within any given cell type of an organism.  
 
The  histone  molecules  are  susceptible  to  a  variety  of  covalent  modifications  including  acetylation, 
phosphorylation, sumoylation, ubiquitination, and methylation among others. Studies in the past decade 
have shown that covalent histone modifications influence chromatin structure and/or function directly or 
indirectly through the recruitment of effector proteins to specific chromatin regions (36-38), thus playing 
positive  or  negative  roles  in  gene  expression.  Generally,  histone  methylation  on  H3K4,  H3K36  and  
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H3K79 and histone lysine acetylation in H3 tails correlates with gene transcriptional activation, while 
histone methylation on H3K9, H3K27, and H4K20 correlates with gene transcriptional repression (38).  
 
Interestingly, it has become increasingly apparent that the misregulation of histone modification, which is 
caused  by  the  deregulation  of  factors  that  mediate  the  modification  installation,  removal  and/or 
interpretation, actively contributes to human cancer. Recent whole genome sequencing data support the 
roles of epigenetic modifiers in cancer progression. For example, UTX, JARID1A, EZH2 are frequently 
found mutated in cancers. In many cases, epigenetic deregulation directly drives cancer. For example, 
MOZ-TIF2 is a recurrent translocation in human AML. MOZ itself is a histone acetyltransferase. The 
oncogenic potential of MOZ-TIF2 fusion protein is dependent on the ability of TIF2 to bind another 
histone acetyltransferase CBP (39).  NUP98-NSD1 is another recurrent translocation in human AML. It 
has been demonstrated that the H3K36 methyltransferase activity of NSD1 is essential for the activation 
of  Hoxa  genes  and  leukemogenesis  in  NUP98-NSD1  leukemia  (40).  As  mentioned  in  the  previous 
sections, MLL rearrangement abrogates the H3K4 methyltransferase activity of MLL protein, but leads to 
aberrantly high H3K79 methylation in MLL target genes, possibly by directly or indirectly recruiting 
DOT1L to the MLL target loci (Figure 1-3).  
 
 
 
 
 
Figure 1-3  H3K79me2 is enriched in MLL target loci HOXA6-11 in  MLL-AF9 rearranged human leukemia cell line 
MOLM and MLL-AF9 rearranged human primary leukemia.  
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As a cell state, cancer is influenced by the epigenetic program that determines how chromatin is packaged 
and what genes are expressed and silenced. We rationalize that targeting epigenetic modifiers may correct 
the deregulated epigenetic program in cancer, and set the cell state back to normal. The FDA approval of 
DNA  methyltransferase  inhibitors  (azacytidine  and  decitabine)  for  the  treatment  of  myelodysplastic 
syndrome (41, 42), and the more recent approval of HDAC inhibitors (vorinostat and romidepsin) for use 
in refractory cutaneous T cell lymphoma (43) have validated epigenetic enzymes as attractive targets for 
pharmaceutical drug development. A number of inhibitors of histone acetyltransferases (HATs), histone 
methyltransferases (HMTs) and histone demethylases (HDMs) are also in various stages of preclinical 
development  (reviewed  in  (44)).  MLL  rearranged  leukemia  is  another  example  of  how  epigenetic 
deregulation contributes to cancer. The involvement of DOT1L enzymatic activity in leukemogenesis 
driven by MLL fusion proteins raises the possibility of targeting DOT1L for therapeutic intervention. In 
our project, we sought to answer whether H3K79 methyltransferase DOT1L is required for a subset of 
MLL  rearranged  leukemia  and  whether  DOT1L  and  its  complex  components  can  serve  as  a  new 
therapeutic target for MLL-rearranged leukemia.  
 
My hypothesis is that DOT1L and its associated  factors play a fundamental role in  MLL-rearranged 
leukemia, and I tested this hypothesis through three specific approaches. 
1. Identify DOT1L complexes in leukemic cells using biochemical approaches and study the function of 
DOT1L complex components in epigenetic regulation via knock-down experiments.  
2. Determine whether Dot1l and aberrant H3K79 methylation is essential for MLL-AF10, CALM-AF10, 
or MLL-AF6 mediated leukemogenesis. MLL-AF10 represents MLL fusions with nuclear partners, and 
MLL-AF6 represents MLL fusions with cytoplasmic partners. 
3. Assess the therapeutic potential of inhibiting the function of Dot1l complex by knock-out of a key 
Dot1l complex component in leukemia.   
 
12 
 
 
Chapter 2  
 
Characterization of the Dot1l Complex in 
Leukemia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Addendum 
 
Liying  Chen  and  Scott  Armstrong  designed  the  experiments.  Liying  Chen  performed  the 
experiments. The mass spectrometry analysis was done with the help of Ross Tomaino in Taplin 
Mass Spec Core Facility.  
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Introduction 
Disruptor  of  Telomeric  Silencing-1  (Dot1)  is  an  evolutionarily  conserved  histone  H3  lysine  (K)  79 
methyltransferase. It was discovered originally in Saccharomyces cerevisiae as a disruptor of telomeric 
silencing. In yeast, Dot1 mediated H3K79 methylation is associated with telomere silencing, meiotic 
checkpoint  control,  and  DNA  damage  response.  In  multicellular  organisms,  Dot1l  is  essential  for 
embryonic development, hematopoiesis, cardiac function, and the development of leukemia (reviewed in 
(45)). 
 
Dot1l is a class I SAM-dependent methyltransferase. It catalyzes the mono-, di-, and tri-methylation of 
H3K79 in a nonprocessive manner (45, 46). Gene inactivation experiments demonstrated that Dot1l is the 
only H3K79 methyltransferase in yeast, flies, and mice (47-49), and despite many studies, no H3K79 
demethylase has yet been reported. Unlike other histone lysine methyltransferase, the enzymatic domain 
of  Dot1l  does  not  belong  to  the  Su(var)3-9,  Enhancer  of  Zeste,  and  Trithorax  (SET)  histone  lysine 
methyltransferase  family  but  shares  structural  similarity  with  the  histone  arginine  methyltransferase 
domain  (50,  51).  In  contrast  to  other  histone  methyltransferases  that  modify  the  histone  tails,  Dot1l 
catalyzes the methylation of lysine in the globular domain of histone H3.  Interestingly, characterization 
of DOT1L enzymatic activity revealed that DOT1L requires the nucleosome as its substrate (52). The fact 
that most histone methyltransferases have activity on structures as simple as H3 tail peptides but DOT1l 
has  minimal  activity  on  recombinant  H3  or  core histones,  suggests  that  the  activity  of DOT1L  may 
recognize  other  features  of  the  nucleosome.  In  agreement  with  the  substrate  preference,  the  crystal 
structure of DOT1L suggested a broad interaction surface between DOT1l, DNA, H3/H4 tetramer and 
H2A/H2B dimer.  
DOT1l was brought to the attention of oncologists by Yi Zhang’s paper which revealed the interaction 
between DOT1l and AF10, a gene recurrently fused with MLL and CALM in AML and T-ALL patients  
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(29, 53). Then it was found that another MLL-fusion partner, ENL, co-purified with DOT1L (28).  It was 
found later by several other biochemical studies that Dot1l directly or indirectly interacts with MLL 
fusion partner AF4, AF17 and AF9 (26, 27, 54). Indeed, the H3K79 hypermethylation associated with 
MLL-target genes is remarkable in MLL-AF4 and MLL-AF9 mouse leukemia and human leukemia. Like 
H3K4  methylation  and  H3K36  methylation,  H3K79  methylation  is  usually  associated  with  active 
transcribed region. However, in MLL-rearranged leukemia, H3K79 methylation, but not H3K4 or H3K36 
methylation, is much higher at MLL targets than non-MLL targets that have similar gene expression 
levels,  suggesting  Dot1l  and  H3K79  methylation  may  be  involved  in  driving  the  leukemia.  Using  a 
conditional knock-out mouse model, our lab as well as other labs have recently shown that Dot1l is 
required for transformation of murine bone marrow cells with MLL-AF9 and MLL-GAS7, but not with 
E2a-Pbx1(25, 55-57). One of the hypotheses is that Dot1l is attracted to MLL-fusion by the fusion partner. 
However, recent studies assessing the MLL-fusion complex either in its respective MLL-fusion leukemia, 
or  in  293T  overexpression  system,  failed  to  find  DOT1l  co-purification.  Furthermore,  detailed 
biochemical studies showed the interaction of DOT1l and ENL, and AEP and ENL, is mutually exclusive 
(16, 58).  
To study the role of the DOT1L complex in the context of leukemia, we purified the DOT1L multiprotein 
complex under physiological conditions in SEMK2 leukemia cells, which represent MLL-AF4 ALL (the 
most common MLL rearrangement) and REH leukemia cells, which is an human ALL cell line with 
wildtype MLL. We aimed to characterize the DOT1L complex in leukemia, to understand the relation 
between super elongation complex and DOT1L complex.  
 
Results 
To understand molecular mechanisms of DOT1L function in MLL-rearranged leukemia, I started with 
biochemical studies of the DOT1L complex in two human pre-B cell leukemia cell lines— SEMK2,  
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which carries the most common MLL translocation MLL-AF4, and REH, which has germline MLL. In 
order to obtain best recovery efficiency and purity, I took advantage of a recently described technique for 
metabolic  biotin  and  FLAG  double  tagging  of  protein  in  mammalian  cells  (59,  60)  (Figure  2-1A). 
SEMK2 and REH cell lines that stably express the E. coli biotin ligase BirA alone (as a control), or BirA 
and  DOT1L  with  a  FLAG  epitope  followed  by  a  23  amino-acid  BirA  recognition  motif  have  been 
generated.  To  minimize  spurious  association  caused  by  overexpression,  cell  lines  that  express 
recombinant DOT1L at levels similar to the endogenous levels were used for subsequent nuclear protein 
extraction  and  complex  characterization  (Figure  2-1B).  Western  blot  showed  that  H3K79  is 
hypermethylated when DOT1L is overexpressed, suggesting that the recombinant DOT1L is functional in 
vivo (Figure 2-1B). Nuclear extraction and affinity purification of FLAG-Bio-DOT1L was performed. 
Co-purified proteins were separated by SDS-PAGE, trypsinized and analysed by microcapillary liquid 
chromatography/tandem mass spectrometry. The peptide sequences were determined by matching protein 
or  translated  nucleotide
  databases  with  the  acquired  fragmentation  pattern  by  the  software
  program 
SEQUEST  (ThermoFinnigan).  Protein  abundance  was  determined  by  the  presence  of  unique  peptide 
sequences, and proteins identified in SEM-BirA or REH-BirA cells were considered as background/noise. 
Together,  four  independent  experiments  were  done  with  SEMK2  cell  line,  and  one  tandem  affinity 
purification  experiment  was  done  with  REH  cell  line.  Figure  2-1C  compared  the  DOT1L  complex 
components identified in MLL-AF4 rearranged SEMK2 cells and MLL-wildtype REH cells, and Table 2-
1 summarizes the functions of DOT1L complex components in SEMK2 cells and REH cells.  
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Figure 2-1 Tandem affinity purification of DOT1L-containing multiprotein complex.  
(A) Schematic representation of experimental procedure. Recombinant DOT1L containing the N-terminal FLAG 
and the BirA recognition site was co-expressed with BirA, a biotin ligase in E. coli. Nuclear extraction and tandem 
affinity  purification  was  followed  by  mass  spectrometry  to  determine  complex  components.  (B)  Western  blot 
analysis of nuclear extracts from SEMK2 cell lines that stably expressing BirA only (left lane) or both BirA and 
Flag-
BioDOT1L  (right  lane).  The  staining  with  anti-DOT1L  antibody  shows  sub-endogenous  level  of  DOT1L 
overexpression,  and  the  staining  with  Streptavidin-horseradish  peroxidase  shows  the  metabolically  labeled 
recombinant DOT1L. Lower panel showed western blot analysis of whole cell lysates from SEMK2 cell lines that 
stably  expressing  BirA  only  or both  BirA  and 
Flag-BioDOT1L, probed with  anti-di-methyl-H3K79  antibody.  (C)  
Graph showing the components of DOT1L complex in SEMK2 (yellow circle) and REH (green circle). 
 
 
As seen in Figure 2-1C and Table 2-1, mass spectrometry results demonstrated that AF10 and AF17 are 
two stable components in DOT1L complex in both SEMK2 and REH cells, while other proteins, such as 
transcription factors, histone modification factors, and scaffold proteins associate with Dot1L in a cell-
type dependent manner. The interaction on the list is further verified by co-immunoprecipitation (co-IP) 
and reciprocal co-IP (see Figure 2-2D).  
B  A 
C  
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Table 2-1 Identification of DOT1L associated proteins in SEMK2 and REH cells 
 
Dot1L complex in SEMK2 (4 experiments in total)  Dot1L complex in REH  (1 experiment in total) 
Name  Average 
Peptide 
Number 
Annotation  Name  Peptide 
Number 
Annotation 
Dot1L   63  H3K79 methyltransferase  Dot1L  58  H3K79 methyltransferase 
AF10  16  MLL fusion partner, putative 
transcription factor 
AF10  17  MLL  fusion  partner,  putative 
transcription factor 
AF17  11  MLL fusion partner, putative 
transcription factor 
AF17  8  MLL  fusion  partner,  putative 
transcription factor 
ILF2  3  NFAT transcription factor  TCOF1  7  Treacher Collins-Franceschetti 
syndrome 1 isoform a 
HDAC1  3  Histone deacetylase 1  ARHGEF2  5  Rho  guanine  nucleotide 
exchange factor 2 
MEF2C  1  Transcription  activator  in  B 
cells 
GTF2I  2  General    transcription  factor 
II-I 
COE1  (2)*
1  Early B-cell factor  SMC2  2  Structural  maintenance  of 
chromosomes protein 2 
CDK9  (1)*
2  Transcriptional  elongation 
factor 
PCM1  2  Pericentriolar  material  1 
protein 
NPM1  (5)*
3  Nucleophosmin,  involved  in 
ribosome biogenesis, histone 
assembly, cell proliferation  
NPM1  1  Nucleophosmin,  involved  in 
ribosome  biogenesis,  histone 
assembly, cell proliferation  
      CCAR1  1  Cell  division  cycle  and 
apoptosis regulator 1 
      AHDC1  1  AT  hook  containing  protein 
that  may  interact  with  MLL, 
ENL, AF9, AF10 
Note: I performed one experiment for REH cells with tandem affinity purification and four experiments for SEMK2 
cells, once with single anti-FLAG purification, twice with single strepavidin purification, and once with tandem 
affinity purification. All the listed proteins in SEMK2 cells have repeatedly appeared in SEM-BirA-Dot1L samples 
but not in SEM-BirA control except NPM1, CDK9, and COE1(see*). 
*
1: COE1 was identified once with 2 unique peptides in the tandem affinity purification in SEMK2 cells. 
*
2: CDK9 was identified once with 1 unique peptide in Streptavidin affinity purification in SEMK2 cells. 
*
3: NPM is known to be an abundant and sticky protein in the nucleus. It was detected in both SEM-BirA-Dot1L 
sample and SEM-BirA control in single step purifications, but it was identified only in SEM-BirA-Dot1L and REH-
BirA-DOT1L samples (5 peptides and 1 peptide detected respectively) but not in SEM-BirA or REH-BirA controls 
using tandem affinity purification.  
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Figure 2-2 Characterization of DOT1L complex in leukemia cells. 
(A-C) Size exclusion chromatography of crude nuclear extracts from SEMK2 (A and B) and REH (A and C) cells 
showed that DOT1L complexes elute at the size around 670kD (fractions 90-95) while P-TEFb elute at a broader 
range (enriched infractions 65-95) . Western blot was performed with antibodies against Dot1L, CDK9, cyclinT1 
and RNAPII CTD, respectively. (D) The interaction between DOT1L and AF10/AF17/HDAC1 was confirmed by 
immunoprecipitation. (E) Reciprocal co-IP showed AF10 and AF17 interact with DOT1L in vivo. (F) The molecular 
structure of AF10 and AF17. 
 
 
 
 
A 
B                   SEMK2                                                              C                                 REH 
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To further characterize DOT1L complex, I performed gel filtration on nuclear extracts from SEMK2 and 
REH cells. As shown in Figure 2-2, the DOT1L complex was eluted as a sharp peak about 670kDa in 
both SEMK2 cells and REH cells. In contrast, RNA polymerase II (RNAPII), CDK9 and cyclin T1 were 
all eluted as very broad peaks, consistent with the diversity of RNAPII and P-TEFb containing complexes. 
In our study, RNAPII and P-TEFb subunits were mainly co-eluted at sizes above 1MDa, in agreement 
with recent papers that showed the Pol II elongation complex AEP or SEC at the size of about 1.5MDa 
(17).  
 
There  are  several  important  points  raised  by  this  study.  First,  though  SEMK2  cells  have  MLL-AF4 
translocation,  neither  MLL  or  AF4  is  found  to  interact  with  DOT1L,  suggesting  that  DOT1L  is  not 
recruited  to  MLL  target  loci  through  direct  association  with  MLL-AF4  fusion  protein  or  that  the 
association  is  weak  or  transcient.  Second,  except  CDK9,  none  of  the  DOT1L  complex  components 
identified in leukemic cells appears in AEP or SEC, and the DOT1L complex was eluted at different sizes 
than AEP or SEC, suggesting that the DOT1L complex and AEP or SEC are two distinct complexes. 
Third, proteins that only associate with DOT1L in SEMK2 or REH cells may have biological relevance. 
For  example,  it  has  been  shown  that  transcription  activator  MEF2C  is  highly  expressed  in  MLL-
rearranged AML and its up-regulation may be responsible for the aggressive nature of MLL-rearranged 
AML (61). DOT1L may cooperate with MEF2C to promote homing and invasiveness of MLL-rearranged 
leukemic cells.  
 
As shown in Figure 2-2, the two most stable DOT1L interacting partners are AF10 and AF17. AF10 and 
AF17  were  both  identified  as  MLL  fusion  partners  in  acute  myeloid  leukemias.  They  are  highly 
homologous proteins with similar N-terminal plant homeodomain (PHD) fingers, and C-terminal Leucine 
Zipper (LZ) domain. What are their functions in DOT1L complex? Why does nature evolve two similar 
proteins? We hypothesized that the two proteins serve different functions in vivo. To characterize the  
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function of AF10 and AF17, I started with shRNA-mediated knock-down experiments in human acute 
leukemia cell lines. Five shRNAs against human AF10 and five shRNAs against human AF17 were tested, 
among which shAF10.1 and shAF17.7 showed consistent knock-down in leukemia cell lines (Figure 2-3A 
and 2-3B) and no toxicity in 293T cells.  
 
Figure 2-3 Suppression of AF10 and AF17 have different phenotypes in leukemia. 
(A-B). Reverse transcription and q-PCR showing effective knock-down of AF10 (A) and AF17 (B) 4 days after 
transduction  with  lentivirus  carrying  shRNA  construct.  AF10  and  AF17  expression  levels  were  normalized  to 
GAPDH and expressed relative to control cells which were transduced with lentivirus carrying shRNA against 
Luciferase gene (shLUC, set to 100%). (C) Growth of human ALL cell line SEM (MLL-AF4) and RS4;11(MLL-
AF4), REH (non-MLL-rearranged), and 693  (non-MLL-rearranged) cells after transduction with shAF10.1 and 
shAF17.7. Viable cells were counted every 3 to 4 days, and cell numbers after transduction with shLUC were set as 
100%. Result is representive of 3 indipendent experiments. (D) Growth of human AML cell line MOLM (MLL-AF9) 
and THP (MLL-AF9), HL60 (non-MLL-rearranged), and Kasumi (non-MLL-rearranged) cells after transduction 
with shAF10.1 and shAF17.7. Viable cells were counted every 3 to 4 days, and cell numbers after transduction with 
shLUC were set as 100%. Result is representive of 3 indipendent experiments. Western blot showing AF17 protein 
level after shRNA-mediated knock-down. (E-F) Western blot showing H3K79me2 level 9 days after transduction 
with shRNA (red arrows points to reduced H3K79me2 level) in 4 ALL cell lines (E) and 4 AML cell lines (F). 
A  B 
C 
D 
E 
F  
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Knock-down of AF10 in human leukemia cell lines led to a global decrease of H3K79me2 9 days after 
introduction of shRNA by lentivirus (red arrows, Figure 2-3E and 2-3F), while knock-down of AF17 did 
not significantly affect H3K79me2 level. In addition, AF10 knock-down affected cell viability of MLL-
rearranged leukemia cell line SEM, RS4;11, MOLM, and THP, while AF17 knock-down does not affect 
cell viability (Figure 2-3C and 2-3D). Therefore, AF10 and AF17 may function differently and AF10 is 
more important regarding H3K79 dimethylation by Dot1l. In Chapter 5, I focus more on the role of AF10 
in MLL leukemogenesis. 
Discussion 
The diversity of MLL fusion partners poses a challenge to developing a unified mechanistic model for 
MLL  leukemias.  However,  gene  expression  signatures  of  MLL  rearranged  leukemias  are  remarkably 
similar and can be reliably used to distinguish leukemias with MLL rearrangements from other subtypes. 
Our  lab  has  shown  that  MLL  rearranged  leukemias  with  nuclear  fusion  partners  (12,  25)  and  with 
cytoplasmic fusion partners (see Chapter 4) both have aberrantly high histone methylation at H3K79 in 
MLL target genes. Thus this epigenetic lesion may be involved in driving the gene expression signatures 
in MLL leukemias. The development of molecular therapies to specifically target epigenetic modifiers is a 
promising new field. In this project, I sought to study the requirement of DOT1L complex in several MLL 
rearranged leukemias with dismal prognosis. To understand the function of DOT1L in leukemia and to 
suggest new therapeutic strategies, however, requires information about the DOT1L complex in the right 
context. Therefore we purified DOT1L complex in human acute leukemia cells with the most common 
MLL  rearrangement,  MLL-AF4,  or  without  MLL  rearrangement.  Our  mass  spectrometry  data  showed 
AF10 and AF17 are the two most stable DOT1L-interacting proteins in leukemia cells. Moreover, shRNA 
mediated knock-down of AF10 in human acute leukemia cell lines diminished global H3K79 methylation  
 
22 
 
level and affected the survival of MLL-rearranged leukemia cells, while knock-down of AF17 showed no 
effect on global H3K79 methylation or in vitro leukemia cell survival.  
 
In our study, we purified the DOT1L complex under physiological conditions from human acute leukemia 
cells. While we further characterized the functions of DOT1L complex components, Ali Shilatifard group 
published  the  first  paper  describing  Dot1l  complex,  which  they  called  DotCom.  In  their  study,  they 
overexpressed FLAG-tagged Dot1l in 293T cells and performed mass spectrometry after one-step affinity 
purification. Similar to our study, they also identified AF10 and AF17 in the complex. Besides AF10 and 
AF17, they found two more MLL fusion partner AF9 and ENL, and a scaffolding protein TRRAP in 
DotCom. There are some possibilities to explain the discrepancy between the two studies. First, while the 
human kidney fibroblast cell line 293T is a useful mammalian system to study protein-protein interaction, 
it is known for overexpression of recombinant proteins at an artificially high level, which may pick up 
false interactions that do not happen under the physiological protein concentration. Second, human kidney 
fibroblast cells and human leukemia cells express different sets of proteins. The difference in the cellular 
proteome  may  explain  the  difference  of  DOT1L/Dot1l  interacting  network  in  the  two  studies.  The 
interaction  between  DOT1L  and  MEF2C  or  ILF2  may  have  important  functions  in  hematopoietic 
malignancy, but MEF2C and ILF2 may not be expressed at a detectable level in kidney fibroblasts. It is 
possible that AF9 and ENL are less abundant in human acute lymphoblastic cells than in 293T cells, 
therefore even if they interact with DOT1L in vivo, they will not be identified in our study with human 
ALL cell lines.  
 
Our study brought the function of the AF10-DOT1L complex into sharp focus, leading us to study its role 
in  the  epigenetic  activation  of  gene  expression  and  involvement  in  MLL  rearranged  leukemias.  The 
interaction between AF10 and DOT1L was first discovered in yeast-two-hybrid screen by Yi Zhang’s 
group. They also demonstrated that the C-terminal octapeptide motif-leucine zipper (OM-LZ) domain of 
AF10, which is required for association with DOT1L, is the “minimal” fusion domain necessary and  
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sufficient for bone marrow transformation by MLL-AF10 and CALM-AF10. The PHD finger, 50-80 
amino acids in length, is a common domain that reads histone modifications. It is found in many human 
proteins and is involved in chromatin-mediated gene regulation. For example, the PHD finger in ING2 
and NURF binds to H3K4me3, and the PHD finger in JARID1C binds to H3K9me3. Many histone 
modifying enzymes have well characterized chromatin binding domains, DOT1L, however, does not have 
any known domain to read histone modifications. Although our study with H3 tail peptide binding assay 
failed to identify the histone modification AF10 may read (data not shown), it is still possible that AF10 
completes DOT1L complex function by targeting DOT1L to specific histone modifications.  
 
One straight-forward hypothesis for MLL rearranged leukemia would be that the MLL-fusion partner 
attracts  Dot1l  to  MLL  targets,  promotes  H3K79  methylation  and  gene  transcription.  This  hypothesis 
could explain the mechanisms of MLL-AF10, and possibly MLL-AF9 and MLL-ENL. However, our 
study of DOT1L complex in MLL-AF4 expressing cells did not find AF4 or MLL by mass spectrometry. 
The  DotCom  identified  by  Ali  Shilartifard  group  also  does  not  include  other  common  MLL  fusion 
partners like AF4, CBP, GAS7 or AF6. Moreover, recently it was revealed that AF4, AFF4, AF9 and 
ENL, all of which are MLL fusion partners that exist in the nucleus, form a higher-order transcriptional 
elongation complex called AEP or SEC, with the positive transcription elongation factor (P-TEFb). It was 
demonstrated that AEP or SEC was hijacked to MLL targets in the context of MLL-fusion leukemia, 
contributing to leukemogenesis. Consistent with our study, their studies also showed Dot1l is not part of 
the MLL-fusion-AEP/SEC complex, although H3K79 methylation is aberrantly high at MLL targets. The 
detailed structure-function study revealed that although ENL binds to Dot1l, the binding of Dot1l and 
ENL or AEP and ENL is mutual exclusive. (16, 17) Therefore, how DOT1L is recruited to MLL targets 
in MLL-rearranged leukemias remains elusive and more detailed studies about the functions of DOT1L 
interacting proteins need to be done.  
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It is intriguing that two homologous proteins AF10 and AF17 serve different functions in vivo. Knock-
down of AF10 affects global H3K79 dimethylation level and cellular survival, while AF17 does not. 
When we were characterizing the function of AF10 with knock-out mouse model, a AF17 knock-out 
mouse model was reported  (62, 63). In agreement with our knock-down study, AF17 knock-out has 
minimal effect on H3K79 methylation and hematopoiesis, but plays a role in sodium homeostasis and 
blood pressure control.  
 
 
Material and Methods 
Generation of Dot1l expressing human leukemia cell lines  
pEF-BirA-V5-His, MSCV-BirA-V5-His, pEF-FLAG-Bio-puro, and MSCV-FLAG-Bio-puro were gifts 
from Orkin lab. pEF-FLAG-Bio-DOT1L-puro was generated by amplifying DOT1L cDNA using 5’-ATT 
GGA TCC TGG GGG AGA AGC TGG AGC TGA GAC TGA AG-3’ (forward primers) and 5’-TAT 
AGC TAG CGA ATT CTA GTT ACC TCC AAC TGT GCC GCC TGC CAC CCC-3’ (reverse primer), 
and inserting the cDNA into the BamHI/XbaI sites of pEF-FLAG-Bio-puro vector.  MSCV-FLAG-Bio-
DOT1L-puro was assembled by ligating the DOT1L cDNA fragment and the MSCV-FLAG-Bio-puro 
vector at the EcoRI site. Packaging plasmids VSV.G and M57 gag/pol were used with MSCV plasmids to 
make amphotropic retrovirus carrying BirA and DOT1L. And packaging plasmids pMD2.G and psPAX2 
were used with pLKO plasmids to make lentivirus carrying shRNA. Coding region human AF10, AF17 
and control shRNA in pLKO.1-lentiviral vectors were kindly synthesized by the Harvard/MIT Broad 
Institute RNA consortium (http://www.broad.mit.edu/rnai/trc). A shRNA targeting Luciferase served as 
control.  
Cell culture   
 
25 
 
The following human cell lines were obtained from American Type Culture collection:  
MLL-AF4 rearranged ALL cell line RS4;11 (ATCC CRL-1873),  
MLL wildtype ALL cell line REH (ATCC CRL-8286),  
MLL-AF9 rearranged AML cell line THP-1 (ATCC TIB-202),  
MLL wildtype AML cell line HL-60 (ATCC CCL-240).  
The  following  cell  lines  were  purchased  from  the  Deutsche  Sammlung  von  Mikroorganismen  und 
Zellkulturen (DSMZ, Germany):  
MLL-AF9 rearranged AML cell line MOLM-14 (DMSZ ACC 554),  
MLL wildtype AML cell line KASUMI-1 (DMSZ ACC 220).  
MLL wildtype ALL cell line 697 cells were provided by Dr. Kimberly Stegmaier (Dana Farber Cancer 
Institute).  
MLL-AF4 rearranged ALL cell line SEMK2-M1 are previously described (Faber et al., 2009).  
All the leukemia cell lines were maintained in RPMI-1640 media (Invitrogen) supplemented with heat-
inactivated 10% fetal bovine serum, 2 mM L-glutamine and non-essential amino acids and 50 U/ml 
Penicillin/Streptomycin (all Gibco, Invitrogen, Carlsbad, CA). 293T cells were cultured in DMEM media 
(Invitrogen) supplemented with heat-inactivated 10% fetal bovine serum, 2 mM L-glutamine and non-
essential amino acids and 50 U/ml Penicillin/Streptomycin. All cells were cultured in the appropriate 
medium in a humidified incubator at 37°C in 5% CO2. 
Lentiviral shRNA experiment 
The  knock-down  efficiency  of  different  shRNAs  against  AF10  and  AF17  was  tested  by  q-PCR  and 
western blotting in 293T and human cell lines. The two most efficient shRNAs among the five were 
selected for further experiments. Human leukemia cell lines were transduced with pLKO.1 puro lentiviral 
shRNA against AF10, AF17, or luciferase. Lentiviral particles were produced by cotransfection of 293T 
cells with pLKO.1 constructs and packaging plasmids pMD2.G and psPAX2. Transfections were carried 
out  with  FuGENE  6  (Roche  Diagnostics),  and  virus  was  harvested  48  and  72 hr  after  transfection.  
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Polybrene (Sigma-Aldrich, St Louis, MO) was added to a final concentration of 7 g/ml, and cells were 
overlaid with viral supernatant. Spinocculation was performed at 2250 rpm for 90 minutes at 37°C. 12 
hours after the transduction, media was replaced. 24 hours after transducation, infected cells were selected 
with 2 μg/ml puromycin. Media was replaced with fresh media with 2 μg/ml puromycin and the number 
of viable cells was counted with trypan blue stain under the microscope every 3 days.  
Generation of human leukemia cell lines stably expressing BirA with and without DOT1L 
Amphotropic retroviral supernatants were produced by cotransfection of 293T cells with VSV.G, M57 
gag/pol, and the plasmid of interest using FuGENE6 (Roche Molecular Biochemicals, Indianapolis, IN). 
Virus containing supernatant medium was collected 2-3 days after the transfection. For transduction, 
2,000,000 cells/well were plated into 6 well plates in the appropriate culture media. Polybrene (Sigma-
Aldrich, St Louis, MO) was added to a final concentration of 7 g/ml, and cells were overlaid with viral 
supernatant.  Spinocculation  was  performed  at  2250  rpm  for  90  minutes  at  37°C.  12  hours  after  the 
transduction,  media  was  replaced  with  2  ml  of  the  appropriate  fresh  culture  media.  24  hrs  after  the 
transduction,  cells  were  selected  with  0.5  mg/ml  G418  for  one  week  (for  establishing  BirA 
expressing cells first) or in 0.5 mg/ml G418 and 5 g/ml puromycin (Sigma-Aldrich) for three days (for 
establishing DOT1L expressing cells based on BirA expressing cells), and maintained in 0.5 mg/ml G418 
alone (for BirA expressing cells without DOT1L) or 0.5 mg/ml G418 and 2.5 g/ml puromycin (for BirA 
expressing cells with DOT1L) throughout the remainder of the observation period. Stably transfected 
cells that express lower level of DOT1L were cloned by limiting dilution. 
Large-scale purification of DOT1L complex and proteomic analysis 
Nuclear extracts are prepared simultaneously from BirA expressing cells with and without tagged DOT1L, 
and affinity purification is processed simultaneously. Cell culture were scaled up to 5-10 liter in 850ml 
roller bottles (BD falcon) and kept in a rolling incubator at 37°C in 5% CO2. Crude nuclear extracts were  
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prepared from ∼1 × 1010 cells essentially as described previously (60). Briefly, cells were collected by 
centrifugation  at  2400g  for  5  mins  and  washed  with  ice-cold  1X  PBS  twice.  Cells  were  rapidly 
resuspended with ~5X packed cell volume (PCV) of ice-cold Hypotonic Buffer (10 mM HEPES [pH 7.9], 
1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.2 mM PMSF, 1:100 mammalian protease inhibitor cocktail 
[Sigma]), and centrifuged at 3000 rpm at 4oC for 5 mins. Cells were then resuspended in 3X PCV of ice-
cold hypotonic buffer and incubated on ice for 10 mins to swell cells. And then cells were transfered to 
glass Dounce Homogenizer and slowly homogenized up and down 12 times with type B pestle. Cells 
were checked for cell lysis by examinzation of small aliquot in tyypan blue stain under microscope. 
Homogenate was centrifuged at 4000 rpm at 3300g at 4oC and supernatant was removed. Nuclei was 
resuspended by first adding ½ packed nuclear volume of ice cold low-salt buffer (20 mM HEPES [pH 
7.9], 25% glycerol (v/v), 1.5 mM MgCl2, 0.02 M KCl, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF, 
1:100 mammalian protease inhibitor cocktail [Sigma]) and then adding ½ packed nuclear volume of ice-
cold high-salt buffer (20 mM HEPES [pH 7.9], 25% glycerol [v/v], 1.5 mM MgCl2, 1.5 M KCl, 0.2 mM 
EDTA, 0.5 mM DTT, 0.2 mM PMSF, 1:100 mammalian protease inhibitor cocktail [Sigma]). Nuclei 
suspension was incubated on a rotating wheel for 30 mins at 4oC, and centrifuged at 25,000 g for 30 mins 
at  4oC.  The  supernatant  (nuclear  extract)  was  transferred  to  fresh  tubes  and  the  centrifugation  was 
repeated to remove any insoluble material.  
Nuclear extracts were immediately dialyzed against 50 volumes of BC139K buffer (139 mM KCl, 12 mM 
NaCl, 0.8 M MgCl2, 20 mM Tris-HCl [pH 7.9], 0.5% NP-40, 0.2 mM EDTA, 20% [v/v] glycerol, 1 mM 
dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride, 0.1% mammalian protease inhibitor cocktail) at 
4°C  using  a  10,000-molecular-weight-cutoff  dialysis  cassette  (Pierce).  The  dialysate  was  centrifuged 
twice  at  25,000  ×  g  for  30  min  at  4°C.  Between  50  and  120  mg  of  total  nuclear  protein  was  then 
precleared with protein A/G beads (Roche) for 1 h on a rotating wheel at 4°C. The precleared supernatant 
was incubated with anti-FLAG M2-agarose beads (Sigma) overnight (14 to 16 h) on a rotating wheel. The 
beads were collected by centrifugation and washed four times with cold BC139K buffer on a rotating  
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wheel at 4°C for 15 min each. Bound material was eluted by incubating beads in BC139K containing 0.1 
mg/ml FLAG peptide (Sigma) for 90 min at 4°C on a rotating wheel. Material from four successive 
elutions was pooled and incubated with streptavidin-agarose beads (Invitrogen) for 14 to 16 h at 4°C on a 
rotating wheel. The beads were washed as described above, transferred into BC139 K buffer in which 
NaCl was substituted for KCl, and heated at 95°C to 100°C in Laemmli sodium dodecyl sulfate (SDS) 
sample buffer for 5 min. The eluted material was concentrated using a YM-10 Centricon (Millipore) 
device and resolved by SDS-polyacrylamide gel electrophoresis (PAGE) on 10% acrylamide gels running 
2.5 cm into the separating gel. Proteins were visualized with colloidal Coomassie blue stain (Invitrogen), 
and the lanes were divided into three sections as “low Molecular Weight (MW)”, “medium MW”, and 
“high MW”.  
Excised  acrylamide  gel  sections  were  cut  into  approximately  1-mm
3  pieces.  Gel  pieces  were  then 
subjected to a modified in-gel trypsin digestion procedure (64). Gel pieces were washed and dehydrated 
with acetonitrile for 10 min, followed by the removal of acetonitrile. Pieces were then completely dried in 
a  Speed-Vac.  Rehydration  of  the  gel  pieces  was  done  with  50  mM  ammonium  bicarbonate  solution 
containing 12.5 ng/μl modified sequencing-grade trypsin (Promega) at 4°C. After 45 min, excess trypsin 
solution was removed and replaced with 50 mM ammonium bicarbonate solution to just cover the gel 
pieces. Samples were then placed in a 37°C room overnight. Peptides were later extracted by removing 
the ammonium bicarbonate solution, followed by one wash with a solution containing 50% acetonitrile 
and 5% acetic acid. The extracts were dried in a Speed-Vac (∼1 h) and then stored at 4°C until analysis. 
On  the  day  of  analysis,  the  samples  were  reconstituted  in  5  to  10  μl  of  high-performance  liquid 
chromatography  solvent  A  (2.5%  acetonitrile,  0.1%  formic  acid).  A  nanoscale  reverse-phase  high-
performance liquid chromatography capillary column was created by packing 5-μm C18 spherical silica 
beads into a fused silica capillary (100-μm inner diameter by ∼12-cm length) with a flame-drawn tip (65). 
After equilibrating the column, each sample was loaded onto the column via a Famos autosampler (LC 
Packings). A gradient was formed, and peptides were eluted with increasing concentrations of solvent B  
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(97.5% acetonitrile, 0.1% formic acid). As each peptide was eluted, they were subjected to electrospray 
ionization and fed into an LTQ linear ion-trap mass spectrometer (ThermoFinnigan). Eluting peptides 
were detected, isolated, and fragmented to produce a tandem mass spectrum of specific fragment ions for 
each peptide. Peptide sequences (and, hence, protein identity) were determined by matching protein or 
translated  nucleotide  databases  with  the  acquired  fragmentation  pattern  by  the  software  program 
SEQUEST (ThermoFinnigan) (66).  
Sephacryl S400 gel filtration chromatography 
 
Crude nuclear extracts were prepared from human leukemia cells as described above and dialyzed against 
50 volumes of cold BC100 buffer (100 mM KCl, 12 mM NaCl, 0.8 M MgCl2, 20 mM Tris-HCl [pH 7.9], 
0.2 mM EDTA, 20% [vol/vol] glycerol, 1 mM dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride, 
0.1% protease inhibitor cocktail [Sigma]). The dialysate was centrifuged twice at 25,000 × g for 30 min at 
4°C. The final supernatant (∼15 mg of total protein) was injected into a 5-ml loop of a DuoFlow 
(Bio-Rad) fast protein liquid chromatography apparatus and run over a HiPrep Sephacryl S400 
26/60 column (Amersham Pharmacia Biotech) in cold BC100 buffer at 0.5 ml/min with 
collection of 1-ml fractions. Molecular mass standards were aldolase (177 kDa), catalase (240 
kDa), ferritin (438 kDa), thyroglobulin (670 kDa), and blue dextran (2 MDa).  
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Chapter 3  
 
 
MLL-AF10 and CALM-AF10 Require Dot1l 
in Leukemia Initiation and Maintanence 
 
 
 
 
Addendum:  
 
This chapter is adapted from the original article: 
L. Chen, A. Deshpande, D. Ban a  , K. M. Bernt, S. Dias, C. Buske, S. R. Daigle, V. M. Richon, 
R.  M.  Pollock,  S.  A.  Armstrong.  Abrogation  of  MLL-AF10  and  CALM-AF10-mediated 
transformation  through  genetic  inactivation  or  pharmacological  inhibition  of  the  H3K79 
methyltransferase Dot1l. Leukemia. Dec 4, 2012; PMID: 23138183. 
 
Liying Chen, Aniruddha Deshpande, and Scott Armstrong designed the experiments. Liying 
Chen, Stuart Dias and Aniruddha Deshpande performed the genetic experiments. Liying Chen 
and Deepti Banka performed the pharmacological experiments.   
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Introduction 
 
Chromosomal  translocations  which  encode  fusion  proteins  are  frequently  associated  with  human 
leukemias.  The  t(10;11)(p12;q23)  translocation,  which  encodes  the  MLL-AF10  fusion  protein,  is  a 
recurrent  chromosomal  rearrangement  observed  mainly  in  patients  with  acute  myelogenous  leukemia 
(AML) (67, 68). Another translocation involving AF10, the t(10;11)(p12;q14) translocation, encodes a  
CALM-AF10 fusion protein and is observed in AML, acute lymphoblastic leukemia (ALL) and precursor 
T  lymphoblastic  lymphoma  (69).  Patients  with  AML  harboring  either  MLL-AF10  or  CALM-AF10 
rearrangements  have  a  particularly  poor  outcome  compared  to  patients  whose  leukemia  cells  do  not 
harbor these translocations (70). Thus new therapeutic approaches are clearly needed for patients with 
AF10-rearranged hematopoietic malignancies.  
  
While  similar  motifs  in  the  AF10  portion  are  retained  in  both  MLL-AF10  as  well  as  CALM-AF10 
oncoproteins motifs, MLL and CALM are quite dissimilar proteins. The wild-type MLL (Mixed Lineage 
Leukemia)  protein  positively  regulates  expression  of  homeobox  (Hox)  genes,  and  is  essential  for 
hematopoietic development (14, 71).  MLL possesses multiple N-terminal domains required for target 
gene recognition (72-74), which are retained in  the oncogenic MLL-AF10 fusion protein. MLL also 
possesses a C-terminal H3 lysine 4 (H3K4) methyltransferase domain (75, 76), which activates Hox gene 
expression during normal development but is absent in the fusion protein. On the other hand, wild-type 
CALM (Clathrin Assembly Lymphoid Myeloid leukemia) protein, primarily localized in the cytoplasm, is 
involved in clathrin-mediated endocytosis and has been shown to be involved in erythropoiesis and iron 
metabolism (77, 78). The clathrin binding domain on the C-terminus of CALM is always retained in the 
CALM-AF10 fusion proteins and is sufficient for leukemogenesis when fused with AF10 (79). As a 
fusion partner of both MLL and CALM, wild-type AF10 (ALL-1 fused gene from chromosome 10) is a 
putative transcription factor containing N-terminal Plant Homeodomain (PHD) zinc finger motifs and a 
C-terminal octapeptide motif-leucine zipper (OM-LZ) domain (80). The AF10 OM-LZ domain is always  
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retained in the MLL-AF10 and CALM-AF10 fusion proteins and has been identified as a domain that 
interacts with the histone H3 lysine 79 (H3K79)-specific methyltransferase DOT1L(15, 29). Although the 
mechanism by which the leukemogenic AF10 fusions transform hematopoietic cells has not been fully 
elucidated, it has been suggested that Dot1l interaction with the AF10 OM-LZ domain is critical for 
oncogenesis (29, 53).  
 
H3K79 methylation, catalyzed solely by Dot1l, is a chromatin modification ubiquitously associated with 
actively transcribed genes (81, 82). In human and mouse MLL-AF10 and CALM-AF10 leukemia cells, 
dimethylated H3K79 is typically enriched in the promoter regions of leukemogenic genes, including the 
posterior  Hoxa  cluster  genes  (29,  53).  Furthermore,  the  epigenetic  deregulation  of  these  specific 
leukemogenic genes correlates with aberrant overexpression in leukemia cells (29, 53, 79). Therefore, 
while DOT1L has not been found to be genetically altered in leukemia, its aberrant recruitment and/or 
activity may lead to epigenetic deregulation and overexpression of crucial fusion protein target genes.  
 
Consistent with this model, it has been shown that hematopoietic progenitor cells cannot be transformed 
by MLL-AF10 after being treated with shRNA against Dot1l for one week (29). Moreover, bone marrow 
cells  could  not  be  transformed  by  CALM-AF10  when  a  dominant  negative  form  of  Dot1l  was 
overexpressed (53). Although the knock-down and over-expression approaches have some limitations, 
these results raise the possibility that DOT1L may be a relevant therapeutic target for MLL-AF10 and 
CALM-AF10 leukemia. To determine whether inhibition of DOT1L represents a valid approach to treat 
MLL-AF10 and CALM-AF10 leukemias, we assessed the effects of genetic deletion and pharmacological 
inhibition  of  Dot1l  in  murine  bone  marrow  cells  immortalized  by  MLL-AF10  and  CALM-AF10 
oncoproteins.  Using  genetically  defined  models  of  human  leukemia  that  bear  specific  epigenetic 
perturbations, our study demonstrates that such abnormal chromatin modifications can be specifically 
targeted using a small-molecule inhibitor. These observations are of particular interest in the light of 
mounting evidence for specific epigenetic alterations in several human tumors.   
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Results   
 
H3K79me2  Is  Abrogated  by  Genetic  Inactivation  of  Dot1L  in  MLL-AF10  and  CALM-AF10 
Transformed Bone Marrow Cells.  
We used a Dot1l conditional knockout mouse model, in which the exon encoding the active site of Dot1l 
is flanked by LoxP sites (25), to determine whether Dot1l and H3K79 methylation are indeed required for 
transformation driven by MLL-AF10 and CALM-AF10. We sorted HSC-enriched Lin
-Sca1
+cKit
+ (LSK) 
cells from Dot1l
+/+ and Dot1l
f/f mouse bone marrow cells, and transformed sorted cells with FLAG-MLL-
AF10 or the FLAG-CALM-AF10 minimal fusion (79). The expression of MLL-AF10 and CALM-AF10 
in transformed bone marrow cells was confirmed by western blotting using an antibody against the N-
terminus of MLL and FLAG respectively (Figure 3-1B). Cells were then plated in cytokine-supplemented 
methylcellulose and expanded for 1-2 weeks. The MLL-AF10 or CALM-AF10 expressing cells were 
subsequently transduced with retroviruses encoding either the Cre-Mi-Tomato (Cre) or the control Mi-
Tomato (MIT), sorted for tdTomato positive cells 2 days after transduction, and plated in methylcellulose 
(see Figure 3-1A). Genotyping of tdTomato
+ cells right after sorting showed a complete deletion of Dot1l 
in cells transduced with Cre (Figure 3-2D). Consistent with deletion of Dot1l, H3K79 di-methylation was 
diminished in MLL-AF10 and CALM-AF10 transformed bone marrow cells after transduction with Cre 
(Figure 3-1C and 3-2C).   
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Figure  3-1  Cre-mediated  deletion  of  Dot1l  leads  to  loss  of  H3K79me2  in  MLL-AF10  and  CALM-AF10 
immortalized murine bone marrow cells 
(A) Schematic representation of experimental design. (B) Western blot showing the expression of MLL-AF10 using 
anti-MLL antibody and FLAG-CALM-AF10 using anti-FLAG antibody in transformed bone marrow cells. Total H3 
was used as a control. (C) Western blot showing the loss of H3K79 methylation 7 days after transduction with Cre 
or MIT. 
 
Loss of Dot1l Inhibits Transformation by MLL-AF10 or CALM-AF10 
We next evaluated the effects of genetic deletion of Dot1l on LSK cells transformed by MLL-AF10 or 
CALM-AF10. Deletion of Dot1l significantly reduced the colony forming potential in both cases (Figure 
3-2A). The number of colonies was significantly decreased in the first week. In addition, Dot1l
-/- colonies 
were morphologically distinct. While the majority of cells after transduction with MIT formed “blast-
li e” compact and  hypercellular colonies, cells after transduction  with Cre formed smaller and  more 
diffuse colonies (Figure 3-2B). Moreover, Wright-Giemsa staining showed that the Cre-transduced cells 
have a larger cytoplasm and smaller nucleus, consistent with myeloid differentiation. We then verified the  
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status of the Dot1l locus in the remaining cells harvested at different time points after Cre transduction. 
Figure 3-2D demonstrates that 3 days after transduction only the excised allele can be detected. However, 
at the end of the first round of plating (day 9), the surviving cells have various degree of deletion, and at 
the end of the second round of plating (day 16), only the non-deleted allele can be detected. The fact that 
a small number of non-deleted cells outgrew in two weeks demonstrates a high selective pressure against 
Dot1l deleted cells. 
   
We then assessed changes in expression of select MLL-fusion target genes in MLL-AF10 transformed 
bone  marrow  cells  after  the  loss  of  Dot1l.  The  N-terminus  of  MLL  binds  to  leukemogenic  genes, 
including 5’ Hoxa cluster genes and Meis1, and the binding property is retained in MLL-AF10 fusion 
proteins (72, 73). The overexpression of MLL-fusion targets is a key feature of MLL-AF10 leukemia and 
the suppression of these leukemogenic genes, such as Hoxa9, is sufficient to abolish the leukemia (29, 53). 
As shown in Figure 3-2C, targets of MLL-AF10 were down-regulated after Cre-mediated deletion of 
Dot1l, while the expression of a gene that is not an MLL-fusion target, Hoxb4, is not changed. This 
finding demonstrates that Dot1l is required for continued expression of MLL-AF10 target genes which 
further  supports  the  requirement  of  Dot1l  in  MLL-AF10  leukemia.  We  also  assessed  the  expression 
changes of leukemia-related genes in CALM-AF10 transformed LSK cells after loss of Dot1l. It has been 
shown that leu emogenic genes, including 5’ Hoxa cluster genes and Meis1 are overexpressed in both 
CALM-AF10 mouse leukemias and CALM-AF10 positive patient leukemias (83, 84). The suppression of 
these leukemogenic genes, such as Hoxa5, is sufficient to abolish CALM-AF10 leukemia (53). As shown 
in Figure 3-2C, Hoxa5, Hoxa7, Hoxa9, Hoxa10, and Meis1 were all down-regulated after Cre-mediated 
deletion  of  Dot1l,  while  the  expression  of  a  control  gene,  Hoxb4,  did  not  change.    This  finding 
demonstrates that Dot1l is required for maintenance of the transformed phenotype in cells expressing the 
CALM-AF10.  
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Figure 3-2 Loss of Dot1l leads to decreased colony forming potential and increased differentiation of MLL-AF10 or 
CALM-AF10 transformed cells. 
(A) Blast and differentiated colony count of Dot1l-deleted MLL-AF10 (left) or CALM-AF10 (right) transformed 
cells in methylcellulose 9 days after transduction with Cre in comparison to controls (n=3 independent experiments). 
(B) Morphologic changes (10X image of colony morphology in methylcellulose, 40X image of Wright-Giemsa stain) 
and H3K79me2 immunofluorescence (20X image, Alexa 674-H3K79me2 and DAPI nuclear stain) in MLL-AF10 
(left)  or  CALM-AF10  (right)  transformedpreleukemia  cells  9  days  after  transduction  with  Cre.  (C)  Relative 
expression levels of Hoxa5, Hoxa7, Hoxa9, Hoxa10, Meis1, and Hoxb4 on cells 5 days after transduction with Cre 
or MIT. Expression levels were normalized to Gapdh and expressed relative to MIT-transduced cells (set to 100%). 
Error bars indicate the SEM (n=3 independent experiments). (D) Genotyping of transduced bone marrow cells on 
day 3, day 9, and day 16 after transduction of Cre. f: floxed allele. : deleted allele. 
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Figure 3-2 (Continued) 
  
 
38 
 
 
Selective Anti-Proliferative Effect of MLL-AF10 and CALM-AF10 Transformed Cells by the Dot1l 
Inhibitor EPZ004777 
Having  established  that  genetic  inactivation  of  Dot1l  inhibits  H3K79  methylation  and  clonogenic 
potential  of  MLL-AF10  or  CALM-AF10  transformed  cells,  we  investigated  the  efficacy  of  Dot1l 
inhibitors against MLL-AF10 and CALM-AF10 transformed murine bone marrow cells. Recently it has 
been  shown  that  the  Dot1l  inhibitor  EPZ004777  selectively  kills  MLL-rearranged  leukemia  cells, 
including an MLL-AF4 leukemia cell line MV4-11 and an MLL-AF9 leukemia cell line MOLM13, but 
not MLL-germline leukemia cells, including Jurkat and HL-60 (85). However, the response of MLL-
AF10 leukemia cells to a Dot1l inhibitor has not yet been evaluated, and the CALM-AF10 leukemia cell 
line  U937  surprisingly  showed  minimal  response  to  the  inhibitor  (85).  Therefore,  we  performed 
proliferation assays over several days with three independently-transformed mouse LSK cell populations 
with MLL-AF10 or CALM-AF10 in the presence of increasing concentrations of EPZ004777 (up to 10 
M) or DMSO vehicle control. MLL-AF9 transformed cells were included as a positive control, and 
HoxA9 and Meis1 co-transformed (HoxA9/Meis1) cells were included as a non-MLL-rearranged cell line 
control which has been shown to be refractory to Dot1l inhibition (25). As shown in Figure 3-3A, the 
growth of MLL-AF10 and CALM-AF10 cells, as well as MLL-AF9 cells, was dramatically inhibited by 
EPZ004777, while the growth of HoxA9/Meis1 cells was unaffected. The anti-proliferative effect was 
dose-dependent, with an IC50 between 0.1 M to 1 M for MLL-AF10 and CALM-AF10 (Figure 3-3B). 
Similar  to  previous  findings  with  human  MLL-AF9  and  MLL-AF4  leukemia  cell  lines,  the  anti-
proliferative  effect  against  MLL-AF10  and  CALM-AF10-transformed  primary  murine  hematopoietic 
progenitor cells only became apparent after 7 days. Nevertheless, when exposed to EPZ004777 longer, 
MLL-AF10  and  CALM-AF10  transformed  cells  showed  a  dramatic  decrease  in  cell  number,  while 
proliferation of the Hoxa9/Meis1 transformed cells was unaffected. Consistent with the proliferation and 
viability curve, Western blots showed a dose-dependent reduction of H3K79 dimethylation in all cell 
lines after incubation with the Dot1l inhibitor EPZ004777 (Figure 3-3E).    
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Figure 3-3 EPZ004777 selectively inhibits proliferation of MLL-AF10 and CALM-AF10 transformed murine bone 
marrow cells  
(A) Growth of MLL-AF10, CALM-AF10, MLL-AF9, and Hoxa9/Meis1a transformed bone marrow cells during 
several days’ incubation with 10 M EPZ004777. Viable cells were counted and replated at equal cell numbers in 
fresh media with fresh compound every 3–4 days. Results were plotted as percentage of split-adjusted viable cells in 
the  presence  of  10M  EPZ004777  compared  to  DMSO  vehicle  control.  Results  are  representative  of  three 
independent experiments. (B) Dosage effect of EPZ004777 treatment on MLL-AF10, CALM-AF10, MLL-AF9, and 
HoxA9/Meis1a transformed bone marrow cells. Cells were counted and replated at equal cell numbers in fresh 
media with fresh compound every 3–4 days. Results were plotted as percentage of split-adjusted viable cells on day 
17 in media with 0.1 M, 1 M, 10 M of EPZ004777 compared to DMSO control (set as 100%). Results are 
representative of three independent experiments. (C) Time course of Hoxa9 and Meis1 mRNA expression in MLL-
AF10 and CALM-AF10 transformed cells over 10 days of incubation with 10 M EPZ004777 as measured by 
quantitative real-time PCR. Expression levels were normalized to Gapdh and expressed relative to those at day 0 
(set to 100%). Error bars indicate the SEM (n=3 independent experiments).  (D) Quantitative real-time PCR analysis 
of Hoxa9, Meis1, and -Actin mRNA levels in MLL-AF10 and CALM-AF10 transformed cells following 7 days of 
incubation with EPZ004777. Relative mRNA expression levels are plotted as a percentage of those in vehicle-
treated control cells. Error bars represent SEM (n=3 independent experiments). (E) Inhibition of cellular H3K79me2 
levels in MLL-AF10, CALM-AF10, MLL-AF9 or Hoxa9-Meis1a transformed bone marrow cells following 7 days 
of treatment with the indicated concentrations of EPZ004777 as measured by immunoblot analysis of extracted 
histones with an anti-H3K79me2 antibody. 
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We next tested whether the expression of MLL-AF10 and CALM-AF10 target genes was affected after 
EPZ004777 treatment. Hoxa9 and Meis1 overexpression is a hallmark of both MLL-AF10 and CALM-
AF10  leukemia  (29,  83,  84).  We  performed  quantitative  real-time  PCR  to  examine  the  effect  of 
EPZ004777 on Hoxa9 and Meis1 mRNA expression levels in MLL-AF10 and CALM-AF10 transformed 
cells. The mRNA expression levels of Hoxa9 and Meis1 started to decrease within 3 days and became 
significantly lower within 7 days’ treatment with 10 M EPZ004777 (Figure 3-3C). Analysis of cells on 
day 7 of EPZ004777 treatment showed a concentration-dependent decrease of mRNA levels of Hoxa9 
and Meis1, but not -actin, which shows that the decrease in Hoxa9 and Meis1 expression is not caused 
by a general inhibition of gene expression.  
 
Next we determined if the decrease in cell number for EPZ004777 treated MLL-AF10 or CALM-AF10 
transformed  cells  was  due  mostly  to  inhibition  of  cell  proliferation  or  induction  of  apoptosis.  Dot1l 
inhibition  reduced  the  number  of  actively  proliferating  MLL-AF10  cells,  with  an  increase  in  the 
percentage of cells in the G1 or sub G1fractions after 4 days of incubation with 10 M EPZ004777 
(Figure 3-4A). Moreover, a significant increase in the percentage of apoptotic cells after inhibition of 
Dot1l was observed in MLL-AF10 transformed cells compared to DMSO control on day 10 (Figure 3-4B). 
Similarly, Dot1l inhibition reduced the number of CALM-AF10 cells in S-phase, with the majority of 
cells found in G1 after 4 days of incubation with 10 M EPZ004777 (Figure 3-4C). Interestingly, there 
was only a minimal increase in apoptotic cells throughout the length of this experiment (Figure 3-4D), 
suggesting the effect on CALM-AF10  may be more of a cell cycle arrest whereas MLL-AF10 cells 
respond with cell cycle arrest and more pronounced apoptosis.  
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Figure 3-4 EPZ004777 causes cell cycle arrest and apoptosis in MLL-AF10 and CALM-AF10 transformed bone 
marrow cells  
(A)  Cell cycle changes (BrdU/7-AAD flow cytometry) in MLL-AF10 transformed bone marrow cells after being 
treated with 10 M EPZ004777 for 0, 4, 8, or 10 days. Results are representative of two independent experiments. 
(B)  Annexin  V  staining  in  MLL-AF10  transformed  bone  marrow  cells  10  days  after  treatment  with  10M 
EPZ004777 or DMSO control (n = 2 independent experiments). Error bars represent standard error of the mean 
(SEM). (C)  Cell cycle changes (BrdU/7-AAD flow cytometry) in CALM-AF10 transformed bone marrow cells 
after being treated with 10 M EPZ004777 for 0, 4, 8, or 10 days. Results are representative of two independent 
experiments.  (D) Annexin V staining in CALM-AF10 transformed bone marrow cells 10 days after treatment with 
10M EPZ004777 or DMSO control (n = 2 independent experiments). Error bars represent standard error of the 
mean (SEM).  
 
We went on to test whether EPZ004777 treatment affects the colony forming ability and serial replating 
capacity of MLL-AF10 and CALM-AF10 transformed LSK cells in in vitro CFC assays. We cultured 
MLL-AF10 or CALM-AF10 transformed mouse bone marrow cells in methylcellulose based medium 
containing DMSO or 10M EZP004777. MLL-AF10 or CALM-AF10 transformed cells formed large,  
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highly clonogenic compact blast-like colonies in methylcellulose based medium containing DMSO. 
However, MLL-AF10 or CALM-AF10 transformed cells formed significantly fewer compact colonies in 
medium containing 10M EZP004777 starting from the first week (Figure 3-5A). The clonogenic 
potential of MLL-AF10 or CALM-AF10 transformed cells was abrogated after two weeks culture in the 
presence of inhibitor. Cytospin at the end of the first week showed that the majority of EPZ004777-
treated cells have large cytoplasm and small or fragmented nucleus, consistent with myeloid 
differentiation.  
 
To study the effect of pharmacological inhibition of Dot1l in vivo, we pretreated MLL-AF10 and CALM-
AF10 transformed cells in liquid culture with either DMSO or 10M EPZ004777 for 8 days before 
injecting into lethally irradiated recipients (Figure 3-5C). Two weeks after injection, we assessed the 
spleen-colony forming ability with CFU-S assay. MLL-AF10 or CALM-AF10 transformed cells without 
inhibitor treatment formed >10 large spleen colonies in two weeks. In contrast, cells pretreated with 
inhibitor failed to form any large spleen colonies, and instead formed several small and diffuse foci, 
similar to the colonies observed in the in vitro methylcellulose based cultures. These effects on the CFU-S 
forming activity suggest that EPZ004777 may show in vivo efficacy against AF10-fusion transformed 
cells (Figure 3-5D). 
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Figure 3-5 EPZ004777 decreased the colony forming potential and induced differentiation in MLL-AF10 and 
CALM-AF10 transformed bone marrow cells in vitro and EPZ004777 pretreatment diminished spleen-colony 
forming potential in vivo 
(A)  Blast  and  differentiated  colony  count  of  MLL-AF10  or  CALM-AF10  transformed  cells  cultured  in 
methylcellulose based medium in the presence of 10uM EPZ004777 or DMSO vehicle control at the end of 1 week 
or  2  weeks  (n=2  independent  experiments).  (B)  Morphologic  changes  (10X  image  of  colony  morphology  in 
methylcellulose, 40X image of Wright-Giemsa stain) in MLL-AF10 (left) or CALM-AF10 (right) transformed cells 
cultured in methylcellulose based medium containing EPZ004777 for 7 days. (C) Schematic representation of CFU-
S experimental design. (D) The morphology of spleen dissected from mice injected with pretreated MLL-AF10 or 
CALM-AF10 transformed cells.  
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Figure 3-5 (Continued)  
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Dot1l  is  Indispensible  for  the  Initiation  and  the  Maintenance  of  MLL-AF10  or  CALM-AF10 
Leukemia Cells In Vivo 
 
Since  CFU-S  activity  does  not  directly  test  whether  Dot1l  inactivation  impacts  full-blown 
leukemogenesis, we sought to assess the impact of Dot1l deletion on in vivo leukemia initiation and 
maintenance  by  the  leukemogenic  AF10  fusions.  Dot1l
f/f  bone  marrow  cells  were  transformed  using 
retroviral  MLL-AF10  or  CALM-AF10.  In  two  to  three  days,  Dot1l  was  deleted  in  preleukemic-
transformed cells through retroviral delivery of Cre-recombinase. Two days after MIT or Cre transduction, 
GFP
+tdTomato
+ cells were sorted and injected into sublethally irradiated recipients at 5×10
5 cells/mouse. 
Flow cytometric analysis of mouse peripheral blood 102 days after injection showed the propagation of 
Dot1l
f/f MLL-AF10-transformed cells but not Dot1l
-/- MLL-AF10-transformed cells in recipients (Figure 
3-6F).    Mice  injected  with  preleukemic  MLL-AF10-transformed  Dot1l
f/f  cells  all  developed  myeloid 
leukemia with a median of 112 days. However, no leukemia could be generated in mice injected with 
same doses of MLL-AF10-transformed Dot1l
-/- cells (Figure 3-6A). Similar to MLL-AF10, preleukemic 
CALM-AF10-transformed Dot1l
f/f  cells represented an increasing population of GFP
+tdTomato
+ cells in 
recipients’ peripheral blood and ultimately caused myeloid leukemia in recipients (Figure 3-7A and B), 
while CALM-AF10-transformed Dot1l
-/- cells disappeared from the peripheral blood within 2 months 
(data not shown). This result shows that Dot1l is required for in vivo leukemogenesis of mouse bone 
marrow cells transformed by MLL-AF10 as well as CALM-AF10.     
 
We then checked the effect of Dot1l deletion on established mouse leukemia cells. We collected bone 
marrow  cells  from  primary  MLL-AF10  or  CALM-AF10  leukemia  mice,  performed  MIT  or  Cre 
transduction, and sorted GFP
+tdTomato
+ cells for injection into mice. Dot1l
f/f MLL-AF10 leukemic cells 
caused Mac1
+Gr1
+ secondary myeloid leukemia with a median of 81 days after transplantation, while 
MLL-AF10 leukemic cells lacking Dot1l failed to cause any leukemia in mice (Figure 3-6B and 3-6C).  
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Histopathology study showed massive organ infiltration of leukemic cells in mice injected with Dot1l
f/f 
MLL-AF10 (Figure 3-6E). The spleen weight of mice injected with Dot1l
f/f MLL-AF10 was significantly 
higher than that of mice injected with Dot1l
-/- MLL-AF10 (p<0.01, Figure 3-6D). Similar to MLL-AF10, 
Dot1l
f/f  CALM-AF10 leukemic cells resulted in an increasing population of  GFP
+tdTomato
+ cells in 
recipients’ peripheral blood and ultimately caused myeloid leukemia in recipients, while Dot1l
 -/- CALM-
AF10 leukemic cells appeared in peripheral blood initially, but disappeared from peripheral blood within 
38 days (Figure 3-7C). This result shows that Dot1l is also required for the maintenance of MLL-AF10 or 
CALM-AF10 leukemia in vivo.     
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Figure 3-6 Dot1l is required for initiation and maintenance of MLL-AF10-driven leukemia in vivo 
(A)  Survival  curves  for  mice  injected  with  5X10
5  MLL-AF10  transformed  bone  marrow  cells  2  days  after 
transduction with Cre or MIT-control retrovirus and sorting for GFP
+/tdTomato
+ cells. (B) Survival curves for 
secondary recipient mice that received 2X10
5 MLL-AF10 leukemia cells 2 days after transduction with Cre or MIT 
and sorting for GFP
+/tdTomato
+ cells. (C) Immunophenotype of spleen cells from MIT-transduced secondary MLL-
AF10 leukemic mice (a typical AML phenotype: Mac1
+Gr1
+CD3
-B220
-).  (D) Spleen picture and spleen size in 
mice injected with Cre or MIT transduced Dot1l 
f/f MLL-AF10 cells (n=5.*: p<0.01). (E) Morphology of peripheral 
blood smear (40X image of Wright-Giemsa stain) and pathology of organs from MIT transduced secondary MLL-
AF10 leukemic mice (10X H&E stain). (F) Peripheral blood chimerism in mice 102 days after injection of MIT or 
Cre  transduced  MLL-AF10  preleukemic  cells.  Donor  cells  are  GFP
+/tdTomato
+  and  recipient  cells  are  GFP
-
/tdTomato
-. 
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Figure 3-6 (continued) 
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Figure 3-7 Dot1l deleted CALM-AF10 leukemic cells failed to repopulate in secondary recipients.  
 (A) Immunophenotype of spleen cells from MIT transduced Dot1l 
f/f CALM-AF10 leukemic mice (majority of cells 
in the spleen displays an AML immunophenotype: Mac1
+Gr1
+CD3
-B220
-). (B) Morphology of peripheral blood 
smear (40X image of Wright-Giemsa stain) and pathology of organs from moribund mice that were injected with 
MIT  transduced  Dot1l 
f/f  CALM-AF10  cells  (10X  H&E  stain).  (C)  Peripheral  blood  chimerism  in  secondary 
recipients 9 days or 38 days after injection of MIT or Cre transduced Dot1l 
f/f CALM-AF10 leukemic cells. Donor 
cells are GFP
+/tdTomato
+ and recipient cells are GFP
-/tdTomato
-.  
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Discussion 
 
A number of studies have recently demonstrated that DOT1L and H3K79 methylation plays an important 
role in MLL-AF9 (25, 45, 56, 57), MLL-GAS7 (56), and possibly MLL-AFX (56) transformation. In this 
study, we show that loss of Dot1l abrogates in vitro as well as in vivo transformation in MLL-AF10 and 
CALM-AF10 immortalized cells. This genetic approach circumvented the drawbacks of knock-down and 
overexpression approaches, such as off-target effects and problems of non-physiologic protein expression, 
thus strengthening the case for targeting Dot1l therapeutically in leukemias involving AF10 fusions.   
 
Current advances in biology, biochemistry and pharmacology have raised the prospects of highly targeted 
therapeutics that maximize efficacy and minimize systemic toxicity. One outstanding example is targeting 
the fusion protein BCR-ABL kinase by imatinib in chronic myeloid leukemia (86). In our study, we tested 
the  efficacy  of  targeting  Dot1l  in  MLL-AF10  and  CALM-AF10  leukemia.  We  show  that  the  small-
molecular inhibitor of Dot1l EPZ004777 selectively inhibits the proliferation of MLL-AF10 and CALM-
AF10 transformed mouse bone marrow cells but has no effect on HoxA9/Meis1 transformed mouse bone 
marrow  cells.  The  fact  that  Dot1l  is  dispensable  for  transformation  driven  by  ectopically-expressed 
HoxA9 and Meis1 is in agreement with the model that the OM-LZ domain of AF10 present in leukemic 
AF10 fusions recruits Dot1l and activates Hox-Meis target genes through aberrant H3K79 methylation.  
Cells ectopically expressing retrovirally introduced HoxA9 and Meis1 genes are therefore immune to loss 
of H3K79 methylation. It not only demonstrates a strong rationale for inhibiting Dot1l as a strategy to 
target the  AF10 rearranged leukemias, but also is in agreement with previous data that Dot1l is not 
absolutely required for cell proliferation (25). Recent studies showed that although conditional knockout 
of Dot1l leads to pancytopenia and failure of hematopoietic homeostasis in adult mice, the toxicity did not 
develop  until  7-8  weeks  after  Dot1l  inactivation  (57).  More  importantly,  in  vivo  administration  of 
EPZ004777 for 2 weeks leads to extension of survival in a mouse MLL xenograft model with minimal  
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hematopoietic side effects (85). These data provide further support for the continued development of 
DOT1L inhibitors as a potential therapeutic modality for MLL-rearranged and CALM-AF10 leukemias. 
 
Interestingly, Daigle et al. recently demonstrated that the leukemia cell line U937, which harbors the 
CALM-AF10 fusion, was insensitive to EPZ004777 (85).  The U937 cell line is a monocytic leukemia 
cell line in which the CALM-AF10 translocation was first identified in 1996 and it is the only readily 
available human leukemia cell line that carries the CALM-AF10 translocation (87). The long latency of 
CALM-AF10 leukemia in the murine bone marrow transplantation model and incomplete penetrance in 
the transgenic CALM-AF10 model strongly hints at additional collaborating mutations that need to be 
accumulated  for  CALM-AF10  leukemogenesis  (83,  88).  It  is  possible  that  the  U937  cell  line  has 
accumulated other mutations, either during in-vivo leukemogenesis or during in-vitro passages, which 
may  enable  cells  to  circumvent  the  requirement  of  DOT1L  for  leukemia  maintenance  in  vitro.  The 
insensitivity of U937 to DOT1L inhibition is intriguing since both circumstantial evidence from human 
leukemias as well as experimental evidence presented here and from other studies points to a key role for 
the DOT1L methyltransferase in AF10 rearranged leukemias. The DOT1L interacting OM-LZ domain is 
consistently retained in both CALM-AF10 as well as MLL-AF10 patients, and the exclusion of the OM-
LZ domain completely inhibits transforming activity of both the CALM –AF10 as well as MLL-AF10 
fusions in murine models (29, 53). Moreover, the OM-LZ domain is also the minimal portion of AF10 
required for the leukemogenesis for both the aforementioned AF10 fusions (79, 89).  Importantly, our 
studies showing that Dot1l gene ablation as well as pharmacologic Dot1l inhibition demonstrates anti-
leukemic activity demonstrate that DOT1L inhibition could be an attractive therapeutic target in human 
AF10 rearranged leukemias.  Therefore, development of a panel of other AF10 rearranged cell lines or 
primary  human  xenograft  models  would  appear  to  be  warranted  to  assess  the  efficacy  of  DOT1L 
inhibition on human AF10 rearranged leukemia.   
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We and others have recently demonstrated that leukemogenesis mediated by a number of MLL fusions is 
dependent on abnormal H3K79 methylation (25, 29, 45, 56, 57).  It was shown that the Dot1l inhibition in 
these  MLL  leukemias  specifically  interfered  with  the  constitutive  activation  of  MLL-target  genes, 
resulting in abrogation of leukemogenesis mediated by these MLL-fusions. Interestingly, even though the 
CALM-AF10 fusion does not involve MLL as a fusion partner, gene expression studies have shown that 
the transcriptional profiles of CALM-AF10 patient samples bear strong similarities to those of MLL 
patient samples (84, 90). A simplistic explanation for this similarity could be the shared dependence of 
these fusions on aberrant H3K79 methylation for the activation of oncogenic programs. The relation 
between H3K79 methylation and AF10-rearranged leukemias is, however, more complicated. On one 
hand,  aberrant  H3K79  hypermethylation  in  MLL-AF10  and  CALM-AF10  targets  are  required  for 
activation of leukemogenic transcriptional programs and the maintenance of leukemia. On the other hand, 
MLL-AF10  and  CALM-AF10  patient  samples  show  a  global  hypomethylation  of  H3K79,  possibly 
because  the  AF10  fusions  disrupt  normal  AF10  function  (91).  Further  studies  will  focus  on  the 
mechanisms of how abnormal H3K79 methylation patterns are established and how deregulation of a 
single epigenetic modification may act as a driver of leukemias with AF10 rearrangements. 
 
Our  observation  that  MLL-AF10  and  CALM-AF10  fusions  require  Dot1l  for  initiation  as  well  as 
maintenance of leukemia, strongly indicates that pharmacologic inhibition of aberrant H3K79 methylation 
could be of potential clinical benefit in the AF10-rearranged leukemias. Future studies will determine the 
effect  of  pharmacologic  DOT1L  inhibition  on  in  vivo  AF10-rearranged  leukemias  using  syngenic  or 
xenogenic leukemia models. At the moment, such studies are precluded by the poor pharmacokinetic 
properties of the DOT1L inhibitor used in our studies (24). These results could help inform future clinical 
trials with DOT1L inhibitors. 
 
Materials and Methods   
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Mutant Mice 
Mice engineered to harbour LoxP sites flanking exon 5 of Dot1l were generated in our laboratory and 
have been described previously (25). Bone marrow cells from 7-10 week old mice in Dot1l wild-type or 
homozygous  floxed  (Dot1l
f/f)  backgrounds  were  used  for  transformation  assays  and  subsequent 
biochemical experiments.  
Generation of Transformed Murine Cells and Leukemia 
The  MSCV  based  MLL-AF9-IRES-GFP,  HoxA9-IRES-GFP,  and  Meis1a-PGK-Puromycin  constructs 
were described previously (25). The FLAG-CALM-AF10 minimal fusion construct has been described in 
detail earlier (79) and the FLAG-MLL-AF10 construct was generated by fusing amino acids 1-1430 of 
MLL  to  amino  acid  625-1027  of  AF10  in  an  MSCV-IRES-GFP  vector.  The  MSCV-IRES-Tomato 
(MiTomato,  or  MIT)  plasmid  was  a  kind  gift  from  the  lab  of Hassan  Jumaa  (Max  Planck  Institute, 
Freiburg). The cDNA for Cre recombinase was sub-cloned into the MIT plasmid to generate the MSCV-
Cre-IRES-Tomato (Cre-MiTomato, or Cre) construct. Retroviral supernatants were collected from 293-T 
cells  separately  transfected  with  the  plasmids  using  standard  protocols  and  used  for  retroviral  spin 
infections.  Sorted  Lin
-Sca
-1
+cKit
+  (LSK)  cells  from  mouse  bone  marrow  were  used  for  retroviral 
transduction experiments. The LSK cells were transduced with viruses carrying MLL-AF10, CALM-
AF10, MLL-AF9, or HoxA9 and Meis1, and expanded for 2-5 days in methylcellulose M3234 (StemCell 
Technologies, Vancouver, Canada) supplemented with cytokines (6ng/ml IL3, 10ng/ml IL6 and 20ng/ml 
SCF).  MLL-AF10  or  CALM-AF10  transformed  cells  were  then  transduced  with  Cre  or  MIT  and 
expanded in methylcellulose M3234 supplemented with cytokines. After two days, GFP
+Tomato
+ cells 
were  sorted  for  in  vitro  colony  forming  assays,  or  sorted  and  transplanted  into  B6/129  syngeneic 
sublethally irradiated (550 rad) recipients at 5×10
5 cells/mouse. For secondary transplants, whole-bone 
marrow  from  leukemic  mice  was  isolated  and  transduced  with  Cre  or  MIT  on  the  same  day; 
GFP
+Tomato
+ cells were sorted in two days, and transplanted into sublethally irradiated (550 rad) B6/129  
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syngeneic recipients at 5×10
5 cells/mouse for generation of secondary CALM-AF10 leukemia, or non-
irradiated severe combined immunodeficiency (SCID) recipients at 2×10
5 cells/mouse for generation of 
secondary MLL-AF10 leukemia. 
 
Colony Forming Assays 
Colony  forming  cell  (CFC)  assays  were  performed  by  plating  1000  cells  per  ml  of  methylcellulose 
M3234 supplemented with cytokines (6ng/ml IL3, 10ng/ml IL6 and 20ng/ml SCF). On day 6-7 after 
plating,  colonies  were  scored  using  a  Nikon  Eclipse  TS100  microscope  (Nikon,  Tokyo,  Japan)  and 
classified  into  two  categories  -  compact  and  hypercellular  blast-like  colonies  or  small  and  diffuse 
differentiated-type colonies. Colonies were then pooled and used for biochemical assays or replated for 
assessment  of  secondary  replating  potential  at  the  same  concentration.  Cytospin  preparations  were 
performed from 50-100,000 cells. Pictures of colonies and Wright-Giemsa stained cytospin preparations 
were taken using a Nikon Eclipse E400 microscope (Nikon, Tokyo, Japan) and a SPOT RT color digital 
camera (Diagnostic Instruments, Sterling Heights, MI, USA).  
EPZ004777  
EPZ004777 was synthesized by Epizyme (Cambridge, MA). 50 mM stock solutions were prepared in 
DMSO and stored at -20 °C. Serial dilutions of stock solutions were carried out just prior to use in each 
experiment and final DMSO concentrations were kept at, or below 0.02%. 
Cell Proliferation,Viability Assay and Colony-Forming Unit-Spleen (CFU-S) Assay 
For assessment of cell proliferation and viability, cells from three independent transductions for each 
virus were plated, in duplicate, in 96-well plates at a density of 1.5×10
4 cells/well in a final volume of 150 
l. Cells were incubated in the presence of increasing concentrations of EPZ004777 up to 10 M. Viable  
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cell number was counted every 3–4 days for up to 17 days using Trypan blue staining. On days of cell 
counts, growth media and EPZ004777 were replaced and cells split to a density of 1.5×10
4 cells/well. 
Results  were  plotted  as  the  percentage  of  split-adjusted  viable  cells  in  the  presence  of  EPZ004777 
compared to DMSO vehicle control. For CFU-S assays, cells from two independent transductions for 
each virus were plated in 24-well plates at a density of 1.5×10
4 cells/well with 10 M EPZ004777 or 
DMSO control. Growth media and EPZ004777 were replaced on day 4. On day 8, viable cells were 
counted and injected into lethally irradiated (550rad twice) syngeneic recipients at 10
4 cells/mouse. After 
two weeks, mice were euthanized and spleens were collected and fixed using standard protocols. 
 
Cell Cycle and Apoptosis Assays 
MLL-AF10 and CALM-AF10 transformed bone marrow cells were plated in 12-well plates at a density 
of 2×10
5 cells/ml. Cells were incubated with 10 M EPZ004777 or DMSO vehicle control in a final 
volume of 1 ml for up to 10 days during which media with inhibitor were changed every 3 to 4 days. Cell 
cycle analysis was performed after 30 min. of BrdU labeling using BrdU-APC/7AAD kit from BD-
Pharmingen (San Jose, CA, USA) on day 0, day 4, day 8, and day10. Data was acquired on a 4-color 
Becton-Dickinson FACSCalibur flow cytometer and analyzed using BD FACS Diva (San Jose, CA, USA) 
and  Modfit  LT  (Verity  Software  House,  Topsham,  ME,  USA).  Annexin  V  apoptosis  assays  were 
performed on day 10. Cells incubated with 10M EPZ004777 or DMSO vehicle control were washed in 
PBS, resuspended in Ca/HEPES buffer (10 mM HEPES, pH7.4; 140 mM NaCl; 2.5 mM CaCl2) and 
incubated with Annexin V-PE (BioVision Inc., Mountain View, CA) for 20 mins. Data was acquired on a 
4-color Becton-Dickinson FACSCalibur flow cytometer and analyzed using BD FACS Diva. 
 
Western Blotting and Immunofluorescence  
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Histone  purification  was  performed  with  triton  extraction  (1×PBS,  0.5%  TritonX100  and  2  mM 
phenylmethylsulfonylfluoride) followed by acid extraction with 0.2 N HCl as previously described (25). 
Whole cell protein extracts were prepared for detection of MLL-AF10 and CALM-AF10 fusion proteins 
(see  supplemental  data  for  detailed  protocol).  Immunofluorescence  was  done  following  a  previously 
established protocol (21). The following antibodies were used for detection: anti-H3K79me2 antibody 
ab3594 (Abcam, Cambridge, MA, USA), anti-total H3 antibody ab1791 (Abcam, Cambridge, MA, USA), 
anti-MLL  antibody  A300-086A  (Bethyl  Laboratories,  Montgomery,  Texas,  USA),  anti-FLAG  m2 
antibody  F1804  (Sigma-Aldrich);  secondary  antibodies  used:  sheep  anti-mouse  ECL  horseradish 
peroxidase  linked  NA931V,  donkey  anti-rabbit  ECL  horseradish  peroxidase  linked  NA934V  (GE 
healthcare UK limited, Little Chalfont Buckinghamshire, UK), and Alexa 594 conjugated goat anti-rabbit 
antibody A11072 (Invitrogen, Carlsbad, CA, USA). 
Reverse transcription and Real Time PCR 
Total RNA was isolated using Trizol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s 
instruction. The resultant cDNA was generated using the Tetro cDNA synthesis kit (Bioline, Taunton, 
MA, USA). Real time PCR was performed using Taqman probes (Applied Biosystems) on the ABI 7700 
Sequence  Detection  System  (Applied  Biosystems).  Expression  levels  (average  values  and  standard 
deviations of triplicate determinations) were normalized to housekeeping gene GAPDH. All experiments 
were performed with technical duplicates from three individual experiments.   
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Chapter 4  
 
 
Leukemic Transformation by the MLL-AF6 
Fusion Requires Dot1l 
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Introduction 
 
In MLL-rearranged leukemias, the MLL gene is fused to one of more than 60 different partner genes, 
resulting in the formation of oncogenic MLL fusion proteins (2, 5, 92). The partners of MLL are nuclear, 
cytoplasmic  or  membrane  associated  proteins  involved  in  diverse  functional  processes  ranging  from 
chromatin  modification  and  transcriptional  elongation  to  cellular  adhesion,  endocytosis,  cytoskeleton 
organization, and signal transduction (reviewed in (5)). A number of MLL fusion partners, especially 
nuclear proteins such as AF4, AF9, ENL, ELL, and AF10 – fusions of which together account for the vast 
majority of MLL patients – are components of large multi-subunit that control gene expression. Several 
such  complexes  have  been  identified  including  the  transcriptional  elongation  complex  called  super 
elongation  complex  (SEC)  (17)  or  the  AF4/ENL/p-Tefb  complex  (AEP)  (16),  and  the  chromatin 
modifying  Dot1l  complex  (see  Chapter  2  and  (15)).  In  MLL-rearranged  leukemias,  constitutive 
recruitment of one or more of these complexes by chimeric MLL fusion proteins is believed to facilitate 
sustained  expression  of  MLL  target  genes,  resulting  in  leukemic  transformation.  These  complexes 
represent possible targets for pharmacologic inhibition, with several studies demonstrating the importance 
of different components of these complexes to MLL fusion mediated transformation (reviewed in (92)). 
One such promising candidate for therapeutic intervention is the histone methyltransferase Dot1l. Dot1l is 
the only known enzyme catalyzing the methylation of histone H3K79. Studies using various human MLL-
rearranged leukemia cells demonstrate high levels of H3K79 methylation on MLL-fusion target genes 
suggesting that Dot1l may play an important role in leukemia driven by a variety of MLL-fusion proteins 
(12, 25, 55-57, 93). Moreover, a specific small-molecule inhibitor of DOT1L has been shown to have 
selective activity against MLL-rearranged human leukemia cell lines (85) raising hopes for therapeutic 
inhibition of Dot1l as a novel strategy for patients with MLL-rearranged leukemias.    
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Leukemias  with  t(6;11)(q27;q23)  which  encodes  the  MLL-AF6  fusion  protein,  constitute  the  largest 
subgroup of MLL-rearranged leukemias in which MLL is fused with a predominantly cytoplasmic protein 
(2). Retrospective studies have shown that presence of the t(6;11)(q27;q23) predicts a particularly poor 
prognosis (94, 95), and thus new therapeutic approaches are clearly needed. Given the recent studies 
demonstrating an important role for Dot1l in leukemias driven by various MLL-fusion proteins and the 
development of small molecule Dot1L inhibitors, we wondered if the MLL-AF6 fusion protein, where the 
MLL  fusion  partner  is  normally  cytoplasmic  and  thus  unlikely  to  be  associated  with  transcriptional 
complexes, also requires Dot1L to maintain the oncogenic transcription program. MLL-AF6 leukemias 
have  been  modeled  in  mice,  where  it  was  recently  shown  that  the  MLL-AF6  fusion  can  transform 
hematopoietic progenitors in vitro and in vivo, a process dependent on the dimerization activity of the  
Ras-association (RA) domain of AF6 (96). We sought to analyze a potential role for H3K79 methylation 
by conducting a genome-wide analysis of H3K79 dimethylation in MLL-AF6 leukemia cells. We also 
assessed whether transformation by the MLL-AF6 fusion oncogene was dependent on aberrant H3K79 
methylation by genetic or pharmacologic inhibition of the Dot1l histone methyltransferase.  
 
Results   
 
Elevated  H3K79  dimethylation  is  found  on  MLL-fusion  target  genes  in  murine  MLL-AF6 
leukemias  
The  presence  of abnormally  high  levels  of  H3K79 dimethylation  (H3K79me2)  at  MLL-fusion  target 
genes has been shown to be a characteristic of cells bearing MLL fusions with predominantly nuclear 
proteins such as AF9 and AF4. In 2011, Yokoyama et al., demonstrated the co-occurrence of the AEP 
complex, H3K79me2 as well as the MLL-AF6 fusion protein at the chromatin of select MLL target genes 
in the MLL-AF6 positive cell line ML2.  We decided to probe genome wide H3K79me2 in MLL-AF6 
transformed leukemia cells in order to assess whether H3K79 methylation might be involved in driving 
MLL target gene expression more broadly in MLL-AF6 leukemias. We established MLL-AF6 driven  
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leukemias  using  a  bone  marrow  transplantation  model  in  which  Lin
-  Sca-1
+  Kit
+  (LSK)  cells  were 
transformed  with  the  MLL-AF6  fusion  gene.  MLL-AF6  expression  was  confirmed  by  Western  blot 
following overexpression in 293-T cells (Figure 4-1B). All mice that developed leukemia were found to 
have AML with more than 90% of cells expressing the Gr-1 and Mac-1 myeloid markers in the bone 
marrow and spleen (Figure 4-1C), and a concomitant depletion of cells expressing lymphoid surface 
markers (data not shown). Genome wide analysis of H3K79me2 by ChIP-seq using H3K79me2 specific 
antibodies showed high levels of H3K79me2 at well-characterized MLL-target genes (Figure 4-1E). To 
analyze  whether  MLL-target  loci  possessed  higher  relative  levels  of  H3K79me2  than  other  highly 
expressed genes, we compared the average distribution of H3K79me2 on a set of previously defined 
MLL-core  target  genes  (25)  and  a  randomly  chosen  set  of  highly  expressed  genes  as  control.    We 
observed consistently higher deposition of H3K79me2 associated with MLL-fusion core target genes as 
compared to controls (Figure 4-1F).    
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Figure 4-1 H3K79 methylation in MLL-AF6 transformed cells.  
(A)  Schematic  depiction of experimental  design. (B) Immunoblotting showing the  MLL-AF6 fusion protein  in 
control compared to MLL-AF6 expressing cells. Histone H3 is shown as the loading control. (C) Immnostaining of 
cells  from  the  bone  marrow  or  spleen  of  a  representative  moribund  MLL-AF6  leukemic  mouse.  Gr-1:  mouse 
granulocyte cell surface marker; Mac-1: mouse macrophage cell surface marker.  (D) H3K79 dimethylation directly 
correlates with expression levels in MLL-AF6 mouse leukemic cells: Mean H3K79 dimethylation levels of genes 
divided into 4 equally sized groups of different expression levels are plotted. (E) H3K79me2 profiles of select MLL-
AF9 targets.  (F) Level and distribution of H3K79me2 profiles around the TSS of MLL core targets (blue lines) 
compared to 3 sets of size matched randomly chosen highly expressed genes (grey lines).  
B 
C  D 
E 
F 
E  
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In order to assess whether H3K79 methylation is required for MLL-AF6 mediated transformation, we 
transduced LSK cells from mice harboring homozygous floxed Dot1l alleles (Dot1l
fl/fl) or Dot1l wild type 
controls  (Dot1l
+/+)  with  the  retrovirus  encoding  MLL-AF6.  Subsequently,  the  MLL-AF6  transformed 
cells were selected with neomycin and transduced with an MSCV-based retrovirus that expresses Cre 
recombinase  and  tdTomato  (Cre-Mi-Tomato).  TdTomato  positive  cells  were  sorted  and  plated  in 
methylcellulose-based media supplemented with cytokines and replated every week for up to three weeks 
(Figure 4-1A). Controls were MLL-AF6 transformed Dot1l
+/+ LSKs subsequently transduced with Cre-
Mi-Tomato or MLL-AF6 transformed Dot1l
fl/fl LSK cells subsequently transduced with the MSCV-based 
retrovirus without the Cre-recombinase (Mi-Tomato). Immunoblot analysis demonstrated that H3K79me2 
levels  were  significantly  reduced  in  MLL-AF6  transformed  Dot1l
fl/fl  bone  marrow  cells  after  Cre 
expression as compared to controls (Figure 4-2E). 
Dot1l deletion inhibits MLL-AF6 mediated transformation 
In order to characterize the effects of Dot1l loss on MLL-AF6 transformation we first performed colony 
forming assays. We found that Dot1l excision significantly diminished the clonogenic capacity of MLL-
AF6 transformed cells in the first week (Figure 4-2A). In contrast to the dense and compact “blast-li e” 
colonies observed in control vector transduced cells, colonies generated upon Dot1l deletion were mostly 
small and diffuse, and Wright Giemsa stained cytospins of these colonies showed features characteristic 
of monocytic differentiation (Figure 4-2B). Genotyping PCR of the Cre transduced colonies at week 1, 2 
and 3 of replating showed a progressive emergence of the un-excised Dot1l allele, demonstrating eventual 
outgrowth of cells that had escaped deletion of  Dot1l. (Figure 4-2C). These results indicate a strong 
selective pressure against Dot1l deleted cells. As we and others have previously published, we noted the 
lack  of  such  strong  selection  in  HoxA9-Meis1  transformed  LSK  cells,  and  individual  HoxA9-Meis1 
transformed Dot1l excised colonies could be picked and propagated for several weeks (data not shown).  
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These results demonstrate a selective requirement for Dot1l in MLL-AF6 transformed cells, but not all 
transformed cells. 
 
 
        
Figure 4-2 Dot1l deletion impairs the transforming capacity of MLL-AF6 transformed bone marrow cells.  
(A).  Differential  colony  counts  from  Dot1l-excised  MLL-AF6  transformed  cells  7  days  after  Cre  transduction 
compared to vector expressing controls (n=3 independent experiments). (B). Morphological changes in colony and 
cell types upon Dot1l deletion in bone marrow cells immortalized by MLL-AF6 (colonies 10x; cell morphology: 
40x). (C). Genotyping of transduced bone marrow cells on day 3, day 10, and day 17 after transduction of Cre. f: 
floxed allele. △: deleted allele.  (D). Enrichment of H3K79me2 normalized to input DNA on the chromatin locus of 
Hoxa/Meis1 gene promoters  as assessed by q-RT-PCR is shown 6-9 days after  Cre transduction, compared  to 
MiTomato transduced cells cells. (n=2 independent experiments).  (E)Western blot showing a marked decrease in 
H3K79me2 methylation 5 days after transduction with the Cre recombinase compared to control vector (Mi-Tomato) 
transduced  cells.  (F).  Reverse  transcription  and  q-RT-PCR  5  days  after  transduction  with  Cre-Mi-Tomato  or 
MiTomato. Expression levels normalized to Gapdh and expressed relative to MiTomato-transduced cells (set to 
100%) are shown. Error bars indicate the SEM (n=2 independent experiments).  
 
E  F  
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Since aberrant H3K79 methylation at target chromatin is believed to result in inappropriate expression of 
MLL-fusion target genes, we sought to assess the effects of Dot1l deletion on H3K79me2 at select MLL-
fusion  target  genes.  Consistent  with  the  ChIP-seq  data  from  MLL-AF6  leukemias,  we  found  high 
enrichment of H3K79me2 on the promoter proximal regions of the Hoxa cluster genes compared to input 
chromatin (Figure 4-2D dark bars). Cre-mediated excision of Dot1l from these MLL-AF6 transformed 
cells  decreased  H3K79me2  levels  at  the  promoters  of  MLL-target  genes  and  -actin  (Fig.  4-2D). 
Reduction in the levels of H3K79me2 resulted in a specific reduction in the transcript levels of MLL-
targets genes Hoxa9, Hoxa10 and Meis1, but not -actin (Fig. 4-2F). This result demonstrates that similar 
to other MLL-fusion driven leukemias, continued expression of MLL-fusion target genes in MLL-AF6 
leukemias requires continued activity of the Dot1l methyltransferase.  
 
The Dotl1 inhibitor EPZ004777 selectively impairs proliferation of murine MLL-AF6 transformed 
cells  
Since genetic inactivation of Dot1l severely impaired MLL-AF6 transformation, we sought to assess 
whether a specific small molecule inhibitor of Dot1l would similarly affect MLL-AF6 transformed cells. 
The specific small molecule Dot1l inhibitor EPZ004777 has been recently described to selectively impair 
the  proliferation  of  several  MLL-rearranged  human  cell  lines  although  its  impact  on  MLL-AF6 
transformed cells has not yet been tested. We incubated MLL-AF6 transformed LSK cells with increasing 
concentrations (0.1M to 10 M) of EPZ004777 or DMSO vehicle control and assessed cell number over 
several days. MLL-AF9 transformed LSKs and HoxA9/Meis1 transformed LSKs served as positive and 
negative controls respectively. A dose-dependent reduction of H3K79me2 was seen in all the transformed 
cell populations by Western blotting after incubation with EPZ004777 (Figure 4-3A). As shown in Figure 
4-3B, the expansion of MLL-AF6 as well as MLL-AF9 cells was dramatically impaired by EPZ004777, 
while  the  growth  of  HoxA9/Meis1  transformed  cells  was  not  significantly  altered.  Consistent  with 
previous findings with human MLL-AF9 and MLL-AF4 leukemia cell lines, the effects on MLL-AF6  
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transformed  primary  murine  hematopoietic  progenitor  cells  only  became  apparent  after  7  days. 
Nevertheless, when exposed to EPZ004777 for a longer time, MLL-AF6 transformed cells showed a 
dramatic decrease in cell number, while expansion of the HoxA9/Meis1 transformed cells was unaffected. 
We then used qRT-PCR to quantify expression levels of Hoxa9, Hoxa10 and Meis1 in cells exposed to 
EPZ004777. A decrease in Hoxa9, Hoxa10 and Meis1 transcript levels was observed in 3 days, with a 
significant drop at day 7 and day 10 after drug exposure (Figure 4-3C).   
 
To  assess  the  effect  of  EPZ004777  on  the  MLL-AF6  transformed  cells in  more  detail,  we analyzed 
changes in cell cycle and apoptosis upon exposure of the MLL-AF6 transformed cells to EPZ004777 by 
flow cytometry for DNA content and Annexin V staining. Dot1l inhibition reduced the number of actively 
proliferating  MLL-AF6  cells,  with  a  dramatic  increase  in  the  percentage  of  cells  in  the  sub  G1/G1 
fractions after 4 days of incubation with 10 M EPZ004777 (Figure 4-3D). These changes in the cell 
cycle were accompanied by an increase in the percentage of Annexin V positive cells, consistent with 
apoptotic  cell  death  after  EPZ004777  treatment  (compared  to  DMSO  control)  (Figure  4-3E).  These 
findings  demonstrate  that  MLL-AF6  driven  leukemias  are  selectively  sensitive  to  pharmacologic 
inhibition of Dot1l.   
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Figure 4-3 Selective inhibition of MLL-AF6 transformed cells by EPZ004777 
 (A) Growth kinetics of MLL-AF6, MLL-AF9, and HoxA9/Meis1a transformed murine bone marrow cells exposed 
to 10 uM of EPZ004777. Viable cells were counted and replated at equal cell numbers in fresh media with fresh 
compound every 3–4 days. Results were plotted as percentage of split-adjusted viable cells in the presence of 10uM 
EPZ004777 compared to DMSO vehicle control. Results are representative of three independent experiments. (B) 
Inhibition  of  cellular  H3K79me2  levels  in  MLL-AF6,  MLL-AF9  or  Hoxa9-Meis1a  transformed  hematopoietic 
progenitor cells following 7 days of treatment with the indicated concentrations of EPZ004777 as measured by 
immunoblot analysis of extracted histones with an anti-H3K79me2 antibody. (C) Time course of HoxA9 and Meis1 
mRNA expression in MLL-AF6 transformed cells over 10 days of incubation with 10 uM EPZ004777 as measured 
by quantitative real-time PCR. Expression levels were normalized to Gapdh and expressed relative to those at day 0 
(set to 100%). Error bars indicate the SEM (n=3 independent experiments).  (D)  Cell cycle changes (BrdU/7-AAD 
flow cytometry) in MLL-AF6 transformed bone marrow cells after being treated with 10 uM EPZ004777 for 0, 4, 8, 
or 10 days. Similar results were obtained in 2 independent experiments. (E) Annexin V staining in MLL-AF6 
transformed bone marrow cells 10 days after treatment with 10uM EPZ004777 or DMSO control (n = 2 independent 
experiments). Error bars represent standard error of the mean (SEM).  
 
 
Detection of the elevated H3K79me2 at MLL-fusion target genes in a human MLL-AF6 positive cell 
line  
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In order to determine whether human leukemia cells bearing the MLL-AF6 fusion gene also display high 
H3K79me2 on MLL-fusion target genes, we performed genome-wide ChIP-seq for H3K79me2 on the 
human MLL-AF6 positive cell line ML2, with the  MLL-germline cell line HL60 and the MLL-AF9 
positive cell line MOLM-13 as negative and positive controls respectively. Similar to the MLL-AF6 
murine leukemias, ML2 cells showed very high levels of H3K79 dimethylation on the HoxA gene cluster, 
similar to the MLL-AF9 positive MOLM-13 cell line whereas HL60 cells display low to undetectable 
levels of enrichment of this modification at the same locus (Figure 4-4A). H3K79me2 levels at other 
MLL-target genes such as MEF2C were similarly high in ML2 and MOLM-13 as compared to HL60. Of 
note, unlike MOLM-13 cells, the ML2 cell line did not display high H3K79 methylation on the MEIS1 
locus, consistent with a previous report (16). A recent study has published microarray data from patients 
bearing a number of MLL patient samples, which include 11 patients with the MLL-AF6 fusion gene (95). 
We performed an integrative analysis of gene expression from these MLL-AF6 patients with our ChIP-
seq data from the ML2 cell line. Expectedly, when analyzed on a global scale, the levels of H3K79 
dimethylation in ML2 positively correlated with the level of transcript expression in these patients (Figure 
4-1D). In the ML2 cell line, MLL-fusion core targets showed significantly higher levels of H3K79me2 as 
compared to 3 randomly chosen size-matched sets of highly expressed genes (Figure 4-4B). A recent 
study identified the direct binding targets of the MLL-AF6 fusion protein using ChIP-Chip in the human 
t(6;11)(q27;q23) positive ML2 cell line. We observed that mean H3K79me2 levels at these 24 MLL-AF6 
target genes was markedly higher than even the MLL-fusion core target genes (Figure 4-4B). These 
findings  demonstrate  that  similar  to  murine  leukemias,  the  human  MLL-AF6  positive  cell  line  ML2 
harbors elevated H3K79me2 on MLL-fusion target genes.  
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Figure 4-4 Abnormal H3K79me2 on MLL targets in the ML2 cell line.  
(A)  H3K79me2  profiles  of  select  MLL-targets  genes  in  MLL  non-rearranged  HL60  cells,  MLL-AF9  positive 
MOLM 13 cells and the MLL-AF6 positive ML2 cell line. (B) Level and distribution of H3K79me2 profiles around 
the TSS of MLL core targets (blue line) and MLL-AF6 direct targets (gold line) compared to non-targets (grey lines). 
Genes with high levels of expression are depicted with the red line and genes with no expression are marked with 
the blue line. Grey lines indicate H3K79me2 on 3 randomly chosen sets of highly expressed genes. 
 
The Dot1l inhibitor EPZ004777 impairs proliferation of the t(6;11) positive cell line ML2  
In order to determine the effects of small molecule inhibition of DOT1L in human leukemia cells, we 
assessed whether the DOT1L inhibitor EPZ0004777 affected the proliferation, differentiation or survival 
of the ML2 cell line with HL60 and MOLM13 as negative and positive controls respectively. The ML2 
cell line showed sensitivity to EPZ004777, with a significant reduction in cell numbers starting from day 
10 after drug exposure (Figure 4-5A). Despite the fact that H3K79me2 was significantly diminished upon   
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Figure 4-5 Selective inhibition of the ML2 cell line by EPZ004777.  
(A) Effect of EPZ004777 on the proliferation of leukemia cell lines bearing an MLL-AF6 (ML2) or MLL-AF9 
(MOLM-13) fusion, or a cell line lacking an MLL rearrangement (HL60). Cell lines were maintained in the presence 
of increasing concentrations of EPZ004777 0.1, 1 and 10 M. (B) Immunoblots showing the levels of H3K79me2 
upon exposure of the different cell lines to indicated concentrations of EPZ004777 or DMSO carrier controls. (C) 
Cell cycle changes (Hoechst staining) in ML2 cell line upon treatment with 10 M EPZ004777 for 0, 4, 8, or 10 
days.  Similar  results  were  obtained  in  2  independent  experiments  each  having  two  technical  replicates.    (D) 
Percentage of Annexin V positive cells plotted 10 days after treatment with 10 M of EPZ004777 or DMSO control. 
 
exposure to EPZ004777 in all the 3 tested cell lines (Figure 4-5B), only MOLM-13 and ML2 showed 
significant sensitivity to EPZ004777 further supporting the selectivity of this small molecule for MLL-
rearranged cell lines. Exposure of ML2 cells to EPZ004777 resulted in a progressive reduction in cells 
entering the S-phase starting from 3 days after drug exposure with an accumulation in the subG1/G1 
phase (Figure 4-5C left panel). EPZ004777 treatment also led to a modest but statistically insignificant 
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increase in the percentage of Annexin V positive cells, indicating that in contrast to cell-cycle changes, 
the  effects  of  EPZ00477 on  apoptosis  of  ML2  cells  was  not  as  profound  (Figure  4-5C right panel).  
Moreover, the expression of MLL-fusion target genes such as HOXA9 and HOXA10 was significantly 
downregulated starting from day 7 after exposure of the ML2 cells to EPZ004777 (Figure 4-5D). Taken 
together, results from the murine and human MLL-AF6 positive leukemia cells indicate that MLL-AF6 
driven leukemias may show sensitivity to pharmacologic DOT1L inhibition. 
 
Discussion 
 
MLL-AF6 rearrangement is one of the most common MLL fusion events in human AML patients and 
MLL-AF6 fusions are associated with a significantly poor prognosis compared to most other common 
MLL-fusions  (94,  95).  Despite  the  clinical  importance,  there  have  been  few  studies  assessing  the 
mechanisms underlying MLL-AF6 leukemia.  In this study we make the surprising observation that both 
mouse and human MLL-AF6 leukemia cells harbor abnormally high H3K79 methylation on MLL-target 
genes, strongly indicating aberrant DOT1L activity in these leukemias. We further show that inactivating 
Dot1l using a conditional knockout model or by using a Dot1l specific small-molecule inhibitor reduces 
H3K79 methylation on MLL-target genes and dramatically impairs the transforming ability of the MLL-
AF6 fusion gene. The human MLL-AF6 positive cell line ML2 also reflects our findings in the murine 
models, suggesting that DOT1L may play a critical role in human MLL-AF6 leukemia. 
 
It has been hypothesized that MLL fusions may recruit the DOT1L complex or transcriptional elongation 
complexes such as SEC or AEP onto MLL-fusion target loci, resulting in their constitutive and aberrant 
activation  in  MLL  rearranged  leukemia.  However,  the  AF6  protein  in  its  non-rearranged  form  is  a 
cytoplasmic protein localized primarily at adherens junctions and binds to actin filaments (97) , and AF6 
has not been co-purified in any of the described transcriptional elongation complexes or DOT1L complex.  
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Therefore, the targeting of these protein complexes on MLL-fusion loci in MLL-AF6 transformed cells is 
unexpected and it is surprising to discover the involvement of Dot1l and H3K79 methylation in MLL-
AF6 leukemias.  
 
It has been shown that the homo-dimerization domain of AF6 is necessary and sufficient for bone marrow 
transformation  by  MLL-AF6  fusion  (96).  In  addition,  it  has  been  reported  that  other  predominantly 
cytoplasmic MLL fusion partners such as GAS7, AF1p, and SEPT6 also possess oligomerization domains 
and  an  MLL  N-terminal  artificial  homodimer  can  immortalize  mouse  bone  marrow  cells  in  vitro. 
Moreover, one unique MLL rearrangement without any MLL fusion partner, the MLL N-terminal partial 
tandem  duplications  (MLL-PTD),  occurs  in  about  4-7%  human  AML  and  is  associated  with  poor 
prognosis.  Therefore, it is conceivable that the oligomerization of MLL N-terminus itself may change the 
conformation of MLL protein complex, creating docking sites for transcriptional activating factors and/or 
excluding  interaction  with  transcriptional  silencing  factors.  It  will  be  of  great  interest  to  determine 
whether abnormal H3K79 methylation profile exists in MLL-PTD patients, and whether transformation 
by MLL N-terminal artificial homodimer is dependent on H3K79 methylation. 
 
Although further studies are needed to reveal the mechanisms of DOT1L recruitment by MLL fusion 
proteins, our observation that MLL-AF6 leukemias are dependent on aberrant DOT1L activity are of high 
clinical relevance. We and others have previously demonstrated that transformation mediated by other 
oncogenes such as Hoxa9 and Meis1, E2A-PBX, and E2A-HLF is insensitive to Dot1l inhibition (25, 56, 
57).  In  addition,  Daigle  et  al.  has  recently  shown that  MLL  wildtype human  leukemia  cell  lines are 
insensitive  to  pharmacologically  inhibition  of  DOT1L  (85).    These  results  strongly  suggest  that  the 
recruitment of DOT1L is a molecular mechanism that is specific to certain, but not all hematological 
malignancies.  
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In summary, our studies discussed above indicate that several MLL fusions – independent of the normal 
sub-cellular localization of the fusion partner – may directly or indirectly recruit the DOT1L complex for 
constitutive  activation  of  the  MLL  transcriptional  program.  This  potentially  shared  mechanism  of 
transformation  could  prove  to  be  an  attractive  therapeutic  target  in  the  MLL  leukemias.  The  results 
showing that MLL-AF6 mediated transformation is dependent upon Dot1l and can be inhibited using 
small  molecule  inhibitors  could  help  inform  future  clinical  trials  with  clinically  effective  DOT1L 
inhibitors. 
 
Material and Methods 
 
Generation of Transformed Murine Cells and Leukemia 
The MSCV-neo MLL-AF6 construct consists of amino acids 35 to 347 comprising the AF6 N-terminal 
conserved region (NCR) cloned in the MSCV-neo 5’ MLL construct and has been described before (96). 
The Mi-Tomato plasmid was a kind gift from Hassan Jumaa (Max Planck Institute, Frieburg). cDNA for 
the  Cre  recombinase  was  sub-cloned  into  the  Mi-Tomato  plasmid  to  generate  the  Cre-Mi-Tomato 
construct.  Retroviral  supernatants  were  collected  from  293-T  cells  separately  transfected  with  the 
aforementioned plasmids using standard protocols and used for retroviral spin infections. Sorted Lin
-Sca-
1
+cKit
+ (LSK) cells from mouse bone marrow cells were transduced with the MLL-AF6 retrovirus and 
expanded for 2 weeks in methylcellulose M3234 (Stem Cell Technologies) supplemented with cytokines 
(6ng/ml IL3, 10ng/ml IL6 and 20ng/ml SCF) and 1mg/ml of G418. After 2 weeks of selection in G418, 
MLL-AF6 transformed cells were either transplanted into B6/129 syngeneic sublethally irradiated (600 
rad) recipients at 10
6 cells/mouse to generate leukemia in mice, or transduced with either Cre-Mi-Tomato 
or the empty Mi-Tomato control vector in vitro to assess the effects of Cre-mediated Dot1l inactivation in 
colony forming assays. 
Histone extraction and Chromatin IP-sequencing (ChIP-Seq)  
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Histones were extracted by overnight acid extraction using the protocol outlined on the Abcam website 
(www.abcam.com).  Western  blotting  was  done  with  standard  procedures  using  a  10  %  Bis-Tris  Gel 
(Nupage, Invitrogen, Carlsbad, CA, USA) and transferred onto PVDF membranes. The MLL-AF6 fusion 
protein was detected from nuclear extracts from 293T cells transiently transfected with MLL-AF6 using 
an anti-MLL antibody A300-086A recognizing the N-terminal portion of MLL (Bethyl Laboratories, 
Montgomery, Texas, USA) with the anti-total H3 antibody ab1791 (Abcam, Cambridge, MA) as the 
loading control. For assessment of H3K79 methylation, the anti-H3K79me2 antibody ab3594 and anti-
total H3 antibody ab1791 (both from Abcam, Cambridge, MA) were used. Secondary antibodies used 
were  sheep  anti-mouse  ECL  horseradish  peroxidase  linked  NA931V  and  donkey  anti-rabbit  ECL 
horseradish peroxidase linked NA934V (GE healthcare UK limited, Little Chalfont Buckinghamshire, 
UK). ChIP was performed as previously described (Krivtsov et al., 2008; Bernt et al., 2011). Briefly, 
crosslinking was performed with 1% formaldehyde, and the cells were lysed in SDS buffer. DNA was 
fragmented by sonication. ChIP for H3K79me2 was performed using anti-H3K79me2 antibody ab3594 
on human leukemia cell line ML2, MOLM14, and HL60, and three primary mouse MLL-AF6 leukemia 
cells.  Eluted  DNA  fragments  were  analyzed  by  qPCR,  or  barcoded  with  NEBNext  DNA  library 
preparation  kit  (NEB,  Ipswich,  MA)  and  subjected  to  sequencing  on  Illumina  HiSeq  2000  platform. 
Reads were aligned to either mouse genome assembly mm9 or human genome assembly hg19 using 
Bowtie (98) . Genome wide ChIP-Seq data was visualized using the integrated genome viewer (IGV) 
version 2.1 (99). 
Mutant mice 
Dot1l conditional knockout mice in which the active site of Dot1l (Exon5) is flanked by LoxP sites were 
generated in our laboratory and have been described previously (25) . Bone marrow cells from 7-10 week 
old  mice  in  Dot1l 
+/+  or  Dot1l
f/f  backgrounds  were  used  for  transformation  assays  and  subsequent 
biochemical experiments.  
Cell lines  
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The MLL-AF6 positive ML2 cell line (obtained from DSMZ) and the cell lines HL60 and MOLM14 
were grown in RPMI 10% FBS supplemented with 2mM L-glutamine and penicillin/streptomycin. 
Colony forming assays 
Colony forming cell (CFC) assays were performed by plating 1000 tdTomato positive cells per ml of 
cytokine-supplemented methylcellulose M3234 (6ng/ml IL3, 10ng/ml IL6 and 20ng/ml SCF). On day 6-7 
after plating, colonies were scored using the Nikon Eclipse TS100 inverted microscope (Nikon, Tokyo, 
Japan). Since almost all colonies were either compact and hypercellular (blast-like) or small and diffuse 
(consistent with differentiation) under these conditions, colonies were classified into these two categories. 
Cells from pooled colony aggregates were then used for biochemical assays or replated for testing their 
secondary  replating  potential  at  the  same  concentration.  Cell  morphology  was  assessed  by  spinning 
50,000 cells onto glass slides (500 rpm for 10 min) using the Shandon Cytospin 4 cytofuge (Thermo 
Scientific, Waltham, MA). Pictures of colonies and Wright-Giemsa stained cytospin preparations were 
taken using the Nikon Eclipse E400 microscope (Nikon, Tokyo, Japan) and a SPOT RT color digital 
camera (Diagnostic Instruments, Sterling Heights, MI, USA).  
Real-Time PCR 
Total RNA was isolated using Tri ol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s 
instruction. cDNA was generated using the tetro cDNA synthesis kit (Bioline, Taunton, MA, USA) using 
oligo-dT  primers.  Real-time  PCR  was  performed  using  pre-validated  Taqman  probes  (Applied 
Biosystems)  on  the  ABI  7700  Sequence  Detection  System  (Applied  Biosystems).  Primer  and  probe 
information will be provided upon request. Average Ct values were normalized to the housekeeping gene 
GAPDH.  
Cell cycle and apoptosis assays 
Bone marrow cell transformed with MLL-AF6 were plated in 12-well plates at a density of 2×10
5 cells/ml 
and incubated with 10 M EPZ004777 (Epizyme, Cambridge, MA, USA) or DMSO vehicle control in a  
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final volume of 1 ml for up to 10 days. Every 3-4 days, fresh media with inhibitor was replaced. Cell 
cycle analysis was performed after 30 mins of BrdU labeling using BrdU-APC/7AAD kit from BD-
Pharmingen (San Jose, CA, USA) on day 0, day 4, day 8, and day10. Data was acquired on a 4-color 
Becton-Dickinson FACSCalibur flow cytometer and analyzed using BD FACSDiva software (San Jose, 
CA, USA) and Modfit LT (Verity Software House, Topsham, ME, USA). Annexin V apoptosis assays 
were  performed  on  day  10.  Cells  incubated  with  10uM  EPZ004777  or  DMSO  vehicle  control  were 
washed in PBS, resuspended in Ca/HEPES buffer (10 mM HEPES, pH7.4; 140 mM NaCl; 2.5 mM CaCl2) 
and incubated with Annexin V-PE (BioVision Inc., Mountain View, CA) for 20 mins. Data was acquired 
on a 4-color Becton-Dickinson FACSCalibur flow cytometer and analyzed using BD FACSDiva. Human 
leukemia cell line HL60, ML2, and MOLM14 were plated in 12-well plates at a density of 2×10
5 cells/ml 
and incubated with 10 M EPZ004777 (Epizyme, Cambridge, MA, USA) or DMSO vehicle control in a 
final volume of 1 ml for up to 10 days. Every 3-4 days, fresh media with inhibitor was replaced. For cell 
cycle  analysis,  cells  were  fixed  and  permeablized  with  buffer  (1x  PBS;  0.5%  Triton  X100;  1% 
Formaldehyde) for 5 mins, and then stained with 1g/ml Hoechst 33342 (Invitrogen, Carlsbad, CA) in 
staining buffer (1x PBS; 2% FBS) for 30 mins on day 0, day 4, day 8, and day10. Data was acquired on 
the BD LSRII and analyzed using Modfit LT (Verity Software House, Topsham, ME, USA). Annexin V 
apoptosis assays were performed on day 10. Cells incubated with 10uM EPZ004777 or DMSO vehicle 
control were washed in PBS, resuspended in Ca/HEPES buffer (10 mM HEPES, pH7.4; 140 mM NaCl; 
2.5 mM CaCl2) and incubated with Annexin V-APC (BD pharmingen, San Jose, CA, USA) for 20 mins. 
Data was acquired on the BD LSRII and analyzed using FlowJo software (TreeStar Inc., CA).  
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Chapter 5  
The Interaction between Dot1l and Af10 Is 
Required for H3K79 Dimethylation and 
MLL Leukemogenesis 
 
 
 
 
 
Addendum: 
This work was done in collaboration with Aniruddha Deshpande. 
Aniruddha Deshpande, Liying Chen, and Scott Armstrong designed the experiments. Aniruddha 
Deshpande made the Af10 knockout mice and performed genetic experiments with MLL-AF9 
and MLL-AF6 leukemia model. Liying Chen characterized the effect of Af10 deletion on the 
H3K79 methylation pattern and chromatin structure, and performed genetic experiments with 
MLL-AF10 and CALM-AF10 leukemia models. 
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Introduction 
 
Post-translational  modification  of  histones  provides  an  important  regulatory  platform  for  gene 
transcription. It has become increasingly apparent that the misregulation of histone modification, which is 
caused by the deregulation of factors that write, remove and/or read modifications, actively contributes to 
human cancer. DOT1L is the sole H3K79 methylase in yeast, mouse, and human (47-49). There has been 
accumulating evidence indicating that deregulation of DOT1L and H3K79 methylation is involved in the 
development of MLL-rearranged leukemia (25, 55-57, 100).  
 
In previous chapters, we characterized DOT1L complex and validated the clinical relevance of inhibiting 
the DOT1L  complex in leukemias bearing  MLL translocations.  In particular, our proteomic study  of 
DOT1L  complex  in  leukemia  cells  suggested  that  AF10  is  a  key  component  of  DOT1L  complex. 
Suppression  of  Af10  leads  to  a  global  reduction  of  H3K79  dimethylation  and  impaired  survival  of 
leukemia cells (Chapter 2). AF10 is a putative transcription factor with a C-terminal DOT1L binding 
motif designated the OM-LZ domain and N-terminal PHD fingers with unknown function. It was first 
cloned as fusion partners of MLL and CALM in human acute leukemia (70, 87). Recently, several other 
AF10 fusion partners, including NAP1L1, HNRNPH1, and DDX3X, have been identified in human early 
T-cell precursor ALL and T-ALL (101, 102). The fact that all the fusion proteins retain the DOT1L 
binding OM-LZ domain and the suppression of AF10 leads to decrease of H3K79 methylation level 
(Chapter 2) also indicates that AF10 may serve a crucial role in DOT1L complex function in normal 
development and disease progression.  
 
Here we hypothesize that the AF10-DOT1L interaction may be of therapeutic interest for MLL-rearranged 
leukemias. In this chapter, we use a conditional Af10 knock-out mouse model to study the role of Af10 in 
the  epigenetic  activation  of  gene  expression  and  in  leukemia  development.  Our  results  revealed  the 
function of Af10, a key Dot1l complex component, is required for global H3K79 di-methylation and the  
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maintenance of the open chromatin structure of MLL-target genes. In addition, with genetic approaches, 
we confirmed that the Dot1l-AF10 interaction is required in the maintenance of MLL-rearranged leukemia. 
 
Results 
 
We generated conditional knockout mice in which the Dot1l-interacting octapeptide-motif leucine zipper 
(OM-LZ) domain of Af10 was flanked by LoxP sites.  Deletion of the Af10
OM-LZ domain with the Cre 
recombinase is predicted to abrogate the Af10-Dot1l interaction (Figure 5-1A). It is an ideal system to 
study  the  role  of  Af10-Dot1l  complex  in  H3K79  methylation  and  leukemogenesis  by  MLL  fusion 
proteins.  
 
First  we  checked  whether  loss  of  Af10  indeed  affects  H3K79  methylation  in  leukemia  cells.  We 
immortalized  bone  marrow  cells  from  Af10
f/f or  Dot1l
f/f  mice using  Hoxa9/Meis1a,  and  subsequently 
transduced cells with Cre or empty vector MIT/MIY, sorted Tomato
+ or YFP
+ cells and grew them in 
methylcellulose-based culture medium. We picked single cell colonies from the methylcellulose dishes, 
confirmed the deletion by genotyping, and expanded them in methylcellulose culture for two more weeks. 
Western blot of extracted histones from these single cell clones showed that complete deletion of Af10 led 
to a dramatic reduction of H3K79me2, very like deletion of Dot1l did (Figure 5-1C). Interestingly, loss of 
Dot1l seems to have less effect on H3K79me1 level (Figure 5-1C). However, it is not possible to make a 
strong conclusion about changes on H3K79me1 from the western blot. Therefore, I submitted the purified 
histones from Af10 or Dot1l floxed cells and Af10 or Dot1l excised cells to liquid-chromatography-mass 
spectrometry  (LC-MS)  to  compare  the  relative  abundance  of  H3K79me0/1/2/3  with  or  without 
AF10/Dot1l. Consistent with previously published data (56), the mass spectrometry showed both H3K79 
mono- and di-methylation were abrogated in Dot1l knockout cells. In agreement with our western blot, 
mass spectrometry confirmed that H3K79 dimethylation was abrogated in Af10 knockout cells. Strikingly,  
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it is revealed by mass spectrometry that H3K79 monomethylation is still retained in Af10 knockout cells 
(Figure 5-1D). Therefore, we conclude that Af10 is required for di-methylation but not mono-methylation 
of H3K79.  
             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-1 Generation of Af10
f/f mice and abrogation of H3K79me2 in Hoxa9/Meis1-transformed Af10
-/- mouse 
bone marrow cells.  
(A) Schematic representation of Af10 wildtype allele, targeting vector, and floxed allele. Boxes with numbers inside 
indicate exons. OM-LZ: Octapeptide Motif-Leucine Zipper. (B) Schematic representation of generation of Af10 and 
Dot1l deleted Hoxa9/Meis1 transformed cell clones. Bone marrow cells from Af10
f/f or Dot1l
f/f mice were 
immortalized by retroviral transduction of Hoxa9/Meis1, and then transduced with either empty vector MIT/MIY or 
Cre.  (C) Western blot showing loss of H3K79me2 but not H3K79me1 in transformed Af10
-/- bone marrow cells. 
Western blot was done with histone extraction from signal cell clones with complete deletion of Af10 or Dot1l. (D) 
H3K79 non-, mono-, di-methylation profile in Dot1l and Af10 deleted cell lines shown by mass spec. (n=2) 
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We have shown that Dot1l and H3K79 dimethylation is required for transformation by MLL-AF9 (25), 
MLL-AF10, CALM-AF10 (100), and MLL-AF6 (Chapter 4). Using our Af10
OM-LZ knockout mouse model, 
we confirmed that disruption of Dot1l-Af10 interaction can abrogate H3K79 di-methylation. We then 
sought to study whether Af10 is required for bone marrow transformation by oncogenic fusions in vitro 
and the development of MLL-rearranged leukemias in vivo.  Using MLL-AF9 and MLL-AF6 encoding 
retroviruses, we established immortalized blast-colony forming cultures from mouse bone marrow cells 
bearing Af10
f/f alleles. Deletion of Af10 with Cre-recombinase dramatically reduced H3K79me2 on the 
MLL-target  genes  Hoxa5-10  and  Meis1,  leading  to  downregulation  of  these  genes.    We  performed 
colony-forming cell (CFC) assays from MLL-AF9 transformed cells in the presence or absence of the 
Af10 allele. In the first week, Af10 deletion profoundly impaired the blast-colony forming potential of 
MLL-AF9 as well as MLL-AF6 transformed LSKs and the only clones that could serially replate in 
subsequent passages had escaped Af10 excision. Af10
 deleted colonies were very small and spread-out and 
showed  morphological  features  of  terminal  myeloid  differentiation  (Figure  5-2).  In  contrast, 
HoxA9/Meis1  transformed  LSK  cells  expanded  normally  in  the  absence  of  Af10.  These  results 
phenotypically mirror deletion of Dot1l and demonstrated that Af10, much like Dot1l, is critical for the in 
vitro transforming activity of MLL-AF9 and MLL-AF6 fusion gene, but does not generally inhibit cellular 
proliferation. It is conceivable that Dot1l and H3K79 methylation is required for the overexpression of 
MLL target  genes including Hoxa9 and Meis1a, and as an important partner of Dot1l, Af10 is also 
required  for  MLL-AF6  and  MLL-AF9  mediated  transformation  and  works  upstream  of  Hoxa9  and 
Meis1a.   
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Figure 5-2   Loss of AF10 decreased colony forming potential of MLL-AF6 and MLL-AF9 transformed bone 
marrow cells, similar to loss of Dot1l.  
(A) Schematic depiction of experimental design. (B) Blast and differentiated colony count of AF10–deleted MLL-
AF6  or  MLL-AF9  transformed  cells  in  methylcellulose-based  culture  10  days  after  transduction  with  Cre  in 
comparison  to  MIT  vector  control.  Result  is  representative  of  3  independent  experiments.  (C)  Morphological 
changes in colony and cell types upon AF10 deletion in bone marrow cells immortalized by MLL-AF9 (colonies 
10x; cell morphology: 40x). 
 
We then sought to investigate the potential role of the Af10
OM-LZ domain in the in vivo leukemogenic 
activity of MLL-AF9. We generated primary MLL-AF9 leukemias from  Af10
f/f mouse bone marrow. 
Deletion  of  the  Af10
OM-LZ domain  in  cells  explanted  from  the  MLL-AF9  primary  leukemias  led  to  a 
significant increase in the disease latency in secondary recipient mice (Figure 5-3B). Microarray analysis 
showed that a vast majority of MLL-AF9 target genes were significantly downregulated in Af10
-/- as 
compared to Af10
f/f wildtype MLL-AF9 leukemias (Figure 5-3C-D). However, the Af10
OM-LZ deleted cells 
could still eventually cause leukemia. This is intriguing given that Af10
OM-LZ  deletion, similar to Dot1l 
deletion, leads to a significant reduction in H3K79 dimethylation as well as MLL-target gene expression. 
A more detailed analysis of H3K79 methylation using mass spectrometry revealed that global levels of 
A 
B  C  
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H3K79 mono-methylation were largely unchanged in Af10
OM-LZ deleted cells, and global levels of H3K79 
dimethylation  was  diminished  by  90%.  The  residual  H3K79  dimethylation  level,  which  was  not 
detectable in in vitro transformed Af10
-/- cells, may be caused by in vivo selection favoring cells with 
relatively high H3K79 dimethylation in the absence of Af10. One possible explanation of Af10
-/- MLL-
AF9 leukemia would be that the residual MLL-AF9 target gene expression seen in Af10
OM-LZ deleted cells 
may be maintained by H3K79 monomethylation or residual H3K79 dimethylation, and though very little, 
is enough for maintaining the leukemia. Another possibility is that other oncogenic genes, like other 
Homeobox genes, may be activated to compensate the loss of MLL target gene expression in the process 
of in vivo leukemogenesis. 
 
 
Figure 5-3 AF10 deletion prolonged survival of secondary MLL-AF9 leukemia in vivo 
(A) Schematic depiction of experiment to study the role of AF10 in MLL-AF9 leukemia maintenance. (B) Survival 
curves for secondary recipient mice that received 3X10
5 MLL-AF9 leukemia cells with or without AF10
OM-LZ 
deletion. (C) Gene set enrichment analysis showing enrichment of MLL-AF9 direct targets in “Af10- noc out” 
signature (D) Heat map showing MLL target expression in MLL-AF9 leukemia with or without AF10
OM-LZ deletion. 
Expression in Hoxa9/Meis1 leukemia is a negative control. Names of probe sets used in expression array are shown. 
A  B 
C  D  
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As stated in Chapter 3, Dot1l has proven to be required for MLL-AF10 and CALM-AF10 mediated 
transformation of bone marrow cells. Here we want to answer the question whether wildtype Af10 is 
required for fusion oncogene-mediated transformation if the fusion retained OM-LZ domain of Af10. 
Therefore, I transduced bone marrow cells from Af10
f/f mice with MLL-AF10 and CALM-AF10, and 
subsequently  transduced  cells  with  Cre  or  MIT,  sorted  Tomato
+  cells  on  day  3,  and  grew  them  in 
methylcellulose-based culture. Interestingly, the colony forming potential of MLL-AF10 and CALM-
AF10 cells is not affected by loss of endogenous Af10 (Figure 5-4). There is no significant difference in 
the percentage of blast-like colony and there is no morphological difference between Af10 excised and 
Af10 floxed cells (Figure 5-4B). Moreover, I picked 8 single cell colonies from the Cre-transduced dishes 
and 4 single cell colonies from the MIT-transduced dishes on day 9 after transduction with Cre or MIT. 
Most  of  the  Cre  clones  and  the  MIT  clones  can  maintain  proliferation  for  more  than  4  weeks  in 
methylcellulose culture. Genotyping showed that all the Cre-transduced single cell clones have clear 
homozygous Af10 deletion (Figure 5-4), and surprisingly, these Af10
-/- single cell clones have almost no 
H3K79me2 as shown by Western blot (Figure 5-4D).  
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Figure 5-4 AF10 is dispensable for bone marrow transformation by MLL-AF10 as well as CALM-AF10. 
(A) Blast and differentiated colony count of AF10–deleted MLL-AF10 (left panel) and CALM-AF10 (right panel) 
transformed cells in methylcellulose 10 days after transduction with Cre in comparison to controls (n=3 independent 
experiments). (B) Morphology (10X image of colony morphology in methylcellulose, 40X image of Wright-Giemsa 
stain) of established MLL-AF10 and CALM-AF10 AF10
f/f leukemia cells 10 days after transduction with Cre or 
MIT.  (C)  Bone  marrow  cells  from  AF10
f/f mice  were  immortalized  by  MLL-AF10  or  CALM-AF10,  and  then 
transduced with MIT or Cre. Single cell clones were picked and genomic status of AF10 was confirmed by PCR. f: 
floxed allele. △: deleted allele. WT: wildtype allele. (D) Western blot was performed with histone extraction from 
three different Cre clones and three different MIT clones (as control). Left panel: MLL-AF10. Right panel: CALM-
AF10. 
A 
B 
C 
D  
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To understand why MLL-AF9 leukemia is affected by loss of AF10
OM-LZ, but MLL-AF10 leukemia is not 
affected by loss of AF10
OM-LZ and how MLL-AF10 or CALM-AF10 cells survive with a global reduction 
of H3K79me2, I performed ChIP-qPCR from in vitro transformed cells on day 9 after transduction with 
Cre. First, I compared the change of H3K79me2 on the promoter regions of MLL target genes (Hoxa7, 
Hoxa9, Hoxa10, and Meis1) and housekeeping genes (-Actin as an example) and silent genes (Hoxb1 as 
an example) in MLL-AF9 transformed cells after AF10 deletion versus after Dot1l deletion. As shown in 
Figure 5-5, Dot1l deletion, as well as AF10 deletion, led to a significant reduction of H3K79me2 on 
promoters of MLL target genes and housekeeping genes. Next, I compared the effects of loss of AF10 on 
the H3K79me2 levels on the promoter regions of MLL target genes and housekeeping genes in MLL-
AF10  transformed  cells  versus  MLL-AF9  transformed  cells.  As  shown  in  Figure  5-5,  in  MLL-AF9 
transformed cells, loss of AF10 resulted in reduction of H3K79me2 level on both MLL target genes and 
housekeeping genes, while in MLL-AF10 transformed cells, loss of AF10 only resulted in reduction of 
H3K79me2 level on housekeeping genes, but not MLL target gene Hoxa7, Hoxa9, Hoxa10, and Meis1. 
These  MLL  target  genes  are  leukemia-promoting  oncogenes  whose  overexpression  is  sufficient  to 
transform  bone  marrow  cells.  The  fact  that  although  being  globally  decreased  after  loss  of  AF10, 
H3K79me2 level is maintained on the small number of MLL target genes in MLL-AF10 leukemia may 
explain why MLL-AF10 leukemia can survive loss of endogenous AF10. It also suggested that the OM-
LZ domain of AF10 is necessary and sufficient for Dot1l-catalyzed H3K79 methylation in MLL targets. 
The  AF10  OM-LZ  domain  and  H3K79  methylation  does have an  important  role  in  MLL-AF10  and 
CALM-AF10  transformation;  however,  MLL-AF10  and  CALM-AF10  transformed  AF10
OM-LZ  deleted 
cells could be “rescued” by the AF10 OM-LZ domain in the respective fusion protein.  
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Figure 5-5 H3K79me2 ChIP-qPCR from in vitro transformed cells on day 9 after transduction with Cre.  
(A)  Loss of H3K79me2 after deletion of AF10 in MLL-AF9 transformed bone marrow cells. (B) H3K79me2 is 
selectively maintained on the promoters of MLL target genes after deletion of AF10 in MLL-AF10 transformed 
bone marrow cells. 
 
Given that Af10 is required for global H3K79 dimethylation and the expression of MLL-AF9 target genes 
specifically, we sought to explore how Af10
OM-LZ deletion would affect the chromatin structure of different 
gene loci.  The chromatin structure was determined by a nuclease accessibility assay, in which the DNA 
in euchromatin or “open” chromatin region is digested by the nuclease but DNA in heterochromatin or 
“close” chromatin region is not. In Af10
f/f cells, MLL target loci and housekeeping gene loci displayed 
“open” structure with high accessibility, while a silent gene Hoxb1 has low accessibility. Interestingly, 
upon Af10 OMLZ deletion, housekeeping genes still displayed high accessibility while all of the tested 
MLL-target genes become less accessible (Figure 5-6).  
A 
B  
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Figure 5-6 Loss of AF10 decreased the chromatin accessibility of MLL-target genes specifically.  
(A) Schematic representation of nuclease accessibility assay to study chromatin structure. (B) The relative chromatin 
accessibility with and without AF10 deletion is calculated using Rhodopsin as a reference gene. 
 
Discussion 
The results presented here demonstrated that Af10 plays an important role in the conversion of H3K79 
monomethylation to dimethylation. When Af10-Dot1l interaction was abrogated by genetic deletion of 
Af10 OM-LZ domain in our knockout mouse model, global H3K79 dimethylation disappeared, while 
H3K79 monomethylation was largely unchanged. Recently, our lab has reported that aberrant H3K79 
dimethylation  on  MLL  target  loci  controls  the  MLL-fusion  associated  leukemogenic  transcription 
program (25). Here we showed that MLL-fusion associated leukemogenic  transcription program was 
suppressed  in  our  AF10
OM-LZ  deleted  MLL-AF9  leukemia.  Moreover,  we  demonstrated  a  strong 
dependence of MLL rearranged leukemia cells on the Af10-Dot1l complex in vitro and in vivo. Deletion  
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of endogenous Af10
OM-LZ affected in vitro bone marrow transformation by MLL-AF9 and MLL-AF6 and 
prolonged the survival of mice with MLL-AF9 leukemia in vivo, phenotypically mirroring the loss of 
Dot1l. In addition, the AF10 OM-LZ domain in MLL-AF10 or CALM-AF10 fusion protein can maintain 
H3K79 dimethylation in highly specific fusion targets and support in vitro bone marrow transformation 
despite the loss of endogenous Af10
OM-LZ and global H3K79 dimethylation, supporting the important role 
of AF10-DOT1L interaction in the installation of H3K79 dimethylation and oncogenic transformation.  
 
We have previously discovered highly abnormal H3K79me2 pattern at MLL target loci in MLL-AF9 
leukemia as well as MLL-AF6 leukemia, which was unique with respect to other actively transcribed loci 
within  the  same  cell.  This  epigenetic  lesion  in  MLL  target  loci  may  explain  a  specific  and 
nonphysiological dependence of the MLL fusion-driven leukemogenic transcription program on H3K79 
methylation. Our lab has recently shown that deletion of endogenous Dot1l abrogates global H3K79 
methylation in MLL-AF9 but only the expression of MLL-AF9 target genes is affected, suggesting that 
H3K79 methylation is not uniformly involved in maintaining transcription. In this study, we demonstrated 
that genetic disruption of Af10-Dot1l interaction abrogated global H3K79 dimethylation but not H3K79 
monomethylation. Our microarray data comparing the transcription program in Af10
f/f and Af10
-/- MLL-
AF9 cells demonstrated that H3K79 dimethylation is required specifically for the expression of MLL 
target  genes  but  is  dispensable  for  transcription  of  non-MLL-target  loci  which  normally  are  also 
associated with H3K79 dimethylation. Interestingly, our results of nuclease accessibility assay revealed 
that deletion of AF10
OM-LZ domain in MLL-AF9 leukemia led to specific chromatin compaction in MLL 
target loci but not in house-keeping genes like Gapdh or -Actin, suggesting a link between aberrant 
H3K79 dimethylation and open chromatin structure. It is thus of tremendous interest to determine the 
temporal order of aberrant H3K79 dimethylation, the opening of chromatin structure, and transcriptional 
activation  at  MLL  target  genes  during  transformation  by  MLL  fusions.  This  may  be  assessed  by  
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monitoring the dynamic changes of chromatin status, H3K79me2 level, and RNA synthesis at various 
time points after inducing the expression of MLL-AF9 in hematopoietic progenitors. 
 
It has been shown that Dot1l is a nonprocessive enzyme and it adds methyl groups to H3 lysine 79 one at 
a time. In yeast, lower concentration of induced Dot1l expression and expression of partially active Dot1l 
will affect the levels of H3K79me2 and H3K79me3 more than the level of H3K79me1. In addition, the 
conversion  of  H3K79me1  to  H3K79me2  and  H3K79me3  requires  a  complex  epigenetic  network 
involving prior mono-ubiquitination of histone H2B. Therefore, Af10-Dot1l interaction may affect the 
transition between H3K79 mono- to di-methylation by three mutually non-exclusive mechanisms. The 
first possibility is that Af10-Dot1l interaction stabilizes Dot1l protein and prevents it from degradation. 
The  second possibility  is  that  Af10 is  required  for targeting  Dot1l  to  chromatin,  thus  increasing  the 
enzyme concentration in the microenvironment. The third possibility is that Af10-Dot1l is required for the 
optimal  enzymatic  activity  of  Dot1l.  Our  preliminary  result  showed  that  Af10  deletion  in  mouse 
fibroblasts affects the nuclear localization but not the protein stability of ectopically expressed FLAG-
DOT1L-GFP (data not shown). To test whether Af10 functions by targeting Dot1l to chromatin, I tried to 
determine the binding patterns of endogenous Af10 and Dot1l and compare them with the binding pattern 
of H3K4me2/3 and H3K79me2/3. However, my initial ChIP-seq experiments failed due to lack of good 
antibodies against endogenous Af10 or Dot1l.  Future directions will be to generate better antibodies 
against  Af10  and  Dot1l  for  studying  the  mechanism  of  the  installation  and  propagation  of  H3K79 
methylation by Dot1l, and to do an in vitro enzymatic activity assay to determine whether AF10 affects 
the enzymatic activity of DOT1L.  
 
It has been demonstrated by us as well as by others that the normal balance of H3K4 methylation and 
H3K79 methylation is destroyed in MLL-rearranged leukemia (12, 25, 93). In mammalian chromatin, 
H3K4 methylation and H3K79 methylation are two parallel marks that coexist in actively transcribed  
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genes  and  may  share  a  requirement  for  the  PAF  elongation  complex  and  H2B  ubiquitylation.  MLL 
rearrangement affects the H3K4 methylation function by genetic inactivation of one MLL allele, but the 
H3K79  methyltransferase  DOT1L  is  recruited  to  MLL-fusion  target  loci,  resulting  in  much  more 
extensive H3K79 methylation in MLL targets. Although the mechanisms for the involvement of DOT1L-
mediated H3K79 methylation in transcriptional activation are not clear, our study here again confirms that 
MLL-rearranged leukemia is addicted to the epigenetic lesion and suggests another strategy to suppress 
the H3K79 methylation in MLL-rearranged leukemia. 
 
In summary, our findings demonstrated that the Af10-Dot1l interaction plays an important role in H3K79 
dimethylation and MLL-fusion leukemogenesis, suggesting that the AF10-DOT1L interaction may serve 
as an attractive therapeutic target in MLL-rearranged leukemias. Proof-of-concept experiments will be 
needed  to  assess  the  effectiveness  of  pharmaceutically  targeting  Af10-Dot1l  interaction  in  MLL-
rearranged  leukemia.  Further  directions  will  be  to  address  how  Af10  affects  the  transition  between 
H3K79 mono- and di-methylation and how dimethylation affects gene transcription. 
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Materials and Methods 
Mutant Mice 
Mice engineered to harbour  LoxP sites flanking the OM-LZ domain of AF10 were generated in our 
laboratory by Dr. Anirrudha Deshpande. Bone marrow cells from 7-10 week old mice in AF10 wild-type 
or  homozygous  floxed  (AF10
f/f)  backgrounds  were  used  for  transformation  assays  and  subsequent 
biochemical experiments.  
Generation of Transformed Murine Cells and Leukemia 
The  MSCV  based  MLL-AF9-IRES-GFP,  HoxA9-IRES-GFP,  and  Meis1a-PGK-Puromycin,  FLAG-
CALM-AF10-IRES-GFP,  FLAG-MLL-AF10-IRES-GFP,  MLL-AF6-neo  constructs  were  described  in 
Chapter 3 and Chapter 4. The MSCV-IRES-Tomato (MiTomato, or MIT) plasmid was a kind gift from 
the lab of Hassan Jumaa (Max Planck Institute, Freiburg). The cDNA for Cre recombinase was sub-
cloned into the MIT plasmid to generate the MSCV-Cre-IRES-Tomato (Cre-MiTomato, or Cre) construct. 
Retroviral supernatants were collected from 293-T cells separately transfected with the plasmids using 
standard protocols and used for retroviral spin infections. Sorted Lin
-Sca
-1
+cKit
+ (LSK) cells from mouse 
bone marrow were used for retroviral transduction experiments. The LSK cells were transduced with 
viruses carrying MLL-AF10, CALM-AF10, MLL-AF9, MLL-AF6 or HoxA9 and Meis1, and expanded 
for 2-5 days in methylcellulose M3234 (StemCell Technologies, Vancouver, Canada) supplemented with 
cytokines (6ng/ml IL3, 10ng/ml IL6 and 20ng/ml SCF). Transformed cells were then transduced with Cre 
or  MIT  and  expanded  in  methylcellulose  M3234  supplemented  with  cytokines.  After  two  days, 
GFP
+Tomato
+ cells were sorted for in vitro colony forming assays, or sorted and transplanted into B6/129 
syngeneic sublethally irradiated (550 rad) recipients at 5×10
5 cells/mouse. For secondary transplants, 
whole-bone marrow from leukemic mice was isolated and transduced with Cre or MIT on the same day;  
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GFP
+Tomato
+ cells were sorted in two days, and transplanted into sublethally irradiated (550 rad) B6/129 
syngeneic recipients at 5×10
5 cells/mouse for generation of secondary MLL-AF9 leukemia. 
Colony Forming Assays 
Colony  forming  cell  (CFC)  assays  were  performed  by  plating  1000  cells  per  ml  of  methylcellulose 
M3234 supplemented with cytokines (6ng/ml IL3, 10ng/ml IL6 and 20ng/ml SCF). On day 6-7 after 
plating,  colonies  were  scored  using  a  Nikon  Eclipse  TS100  microscope  (Nikon,  Tokyo,  Japan)  and 
classified  into  two  categories  -  compact  and  hypercellular  blast-like  colonies  or  small  and  diffuse 
differentiated-type colonies. Colonies were then pooled and used for biochemical assays or replated for 
assessment  of  secondary  replating  potential  at  the  same  concentration.  Cytospin  preparations  were 
performed from 50-100,000 cells. Pictures of colonies and Wright-Giemsa stained cytospin preparations 
were taken using a Nikon Eclipse E400 microscope (Nikon, Tokyo, Japan) and a SPOT RT color digital 
camera (Diagnostic Instruments, Sterling Heights, MI, USA).  
Western Blotting 
Histone  purification  was  performed  with  triton  extraction  (1×PBS,  0.5%  TritonX100  and  2  mM 
phenylmethylsulfonylfluoride) followed by acid extraction with 0.2 N HCl as previously described (25). 
Proteins were separated on a 10% Bis-Tris gel (Nupage, Invitrogen, Carlsbad, CA, USA), and transferred 
onto PVDF membranes.  The following antibodies were used for detection: anti-H3K79me2 antibody 
ab3594 (Abcam, Cambridge, MA, USA), anti-total H3 antibody ab1791 (Abcam, Cambridge, MA, USA); 
secondary antibodies used: sheep anti-mouse ECL horseradish peroxidase linked NA931V and donkey 
anti-rabbit  ECL  horseradish  peroxidase  linked  NA934V  (GE  healthcare  UK  limited,  Little  Chalfont 
Buckinghamshire, UK). 
 
Mass Spectrometry  
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Histone  was  extracted  from  10
8  cells  with  triton  extraction  (1×PBS,  0.5%  TritonX100  and  2  mM 
phenylmethylsulfonylfluoride) followed by acid extraction with 0.2 N HCl as previously described (25). 
Histone extract was separated by 10% SDS-PAGE gel and stained with comassie stain. Histone bands 
were  cut  out  and  trypsinized  and  subjected  to  LC-MS  analysis.  The  abundance  of  different  form  of 
H3K79  modifications  in  Dot1l
f/f  or  Af10
f/f  cells  was  set  to  1  and  the  relative  abundance  of  different 
modifications in Dot1l
-/- or Af10
-/- celles was compared to that in Dot1l
f/f or Af10
f/f cells, respectively. The 
intensity of the following digested peptides were plotted: Control H3 peptide sequence is YRPGTVALR; 
H3K79me0  represents  unmodified  (EIAQDFK)  H3K79  peptide;  H3K79me1  represents  monomethyl 
(EIAQDFKTDLR) H3K79 peptide; H3K79me2 represents dimethyl (EIAQDFKTDLR) H3K79 peptides. 
H3K79 trimethylation was rare and below the sensitivity of mass spectrometric detection. 
 
Reverse transcription and Real Time PCR 
Total RNA was isolated using Trizol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s 
instruction. The resultant cDNA was generated using the Tetro cDNA synthesis kit (Bioline, Taunton, 
MA, USA). Real time PCR was performed using Taqman probes (Applied Biosystems) on the ABI 7700 
Sequence  Detection  System  (Applied  Biosystems).  Expression  levels  (average  values  and  standard 
deviations of triplicate determinations) were normalized to housekeeping gene Gapdh. All experiments 
were performed with technical duplicates from three individual experiments.  
 
After two rounds of plating cells were harvested and subjected to Chromatin immunoprecipitation (ChIP). 
Chromatin immunoprecipitation was performed similarly as described (25).  Briefly, cells were fixed in 
PBS 1% formalin (v/v) with gentle rotation for 10 minutes at room temperature. Fixation was stopped by 
the addition of glycine (125 mM final concentration). Fixed cells were washed twice in ice-cold PBS, 
resuspended in SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.1). Chromatin was 
sheared  by  sonication  to  about  100-500bp  fragments  using  bioruptor  (diagenode,  Denville,  NJ)  and  
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diluted ten folds with dilution buffer (0.01% SDS, 1.1% Triton-X100, 1.2 mM EDTA, 16.7 mM Tris-HCl, 
pH  8.1,167  mM  NaCl).  Antibodies  against  specific  histone  modifications  or  Dynabeads  M280 
streptavidin beads (Invitrogen) was used to precipitate DNA fragments associated with modified histones. 
Precipitates were washed sequentially with ice cold low salt wash (0.1% SDS, 1% Triton-X-100, 2mM 
EDTA, 20mM Tris-HCl, pH8.1, 150mM NaCl), high salt wash (0.1% SDS, 1% Triton-X-100, 2mM 
EDTA, 20mM Tris-HCl, pH 8.1, 500mM NaCl), LiCl wash (0.25M LiCl, 1% IGEPAL CA-630, 1% 
deoxycholic acid, 1mM EDTA, 10mM Tris-HCl, pH 8.1) and TE wash (1mM EDTA, 10mM Tris-HCl, 
pH 8.1) and eluted in elution buffer (1% SDS, 0.1 M NaHCO3). All buffers except for elution buffer were 
supplemented  with  protease  inhibitor  (Complete  mini  protease  inhibitor  cocktail  tablets,  Roche, 
Indianapolis, IN). Eluted DNA fragments were analyzed by quantitative PCR using promoter specific 
primers  for  Hoxa7  (forward:  CTCTTCTGTTTCCCATCCTGGT;  reverse: 
GGCAATATCCGGGATCCACT),  Hoxa9  (forward:  GGAATAGGAGGAAAAAACAGAAGAGG; 
reverse:  TGTATGAACCGCTCTGGTATCCTT),  Hoxa10  (forward:  CCTTTTTGGTCGACTCGCTC; 
reverse:  CAACACCAGCCTCGCCTCT), Meis1a (forward: TCACCACGTTGACAACCTCG; reverse: 
GCTTTCTGCCACTCCAGCTG),  Hoxb1  (forward:  GGGACTGCCAAACTCTGGC;  reverse: 
CATGTGATCTCTCCCAGGCC)  and  -Actin  (forward:  GGGAACCAGACGCTACGATC;  reverse: 
TTGGACAAAGACCCAGAGGC). Chromatin immunoprecipitation for H3K79me2 and H3K79me1 was 
performed  as  above  using  rabbit  polyclonal  antibodies  from  abcam  (Cambridge,  MA):  ab3594  and 
ab2886, respectively.  For ChIP sequencing, ChIP DNA libraries were made following Illumina ChIP-seq 
library preparation kit and subjected to Solexa sequencing (Illumina). 
 
RNA amplification and gene expression array 
RNA was isolated from 1x10
5 sorted GFP
+/YFP
+ cells using Trizol (Invitrogen, Carlsbad, CA). RNA was 
amplified using the Nugen Ovation Pico WTA system (Nugen, San Carlos, CA), and labeled using the 
Nugen EncoreTM Biotin Module. 5 μg of amplified and labeled DNA was hybridized to Affymetrix 430 
2.A murine microarrays. GenePattern (Reich et al., 2006) release 3.2.3 was used to normalize the raw  
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microarray data using RMA algorithm, preprocess the normalized data using default parameters and find 
differentially expressed probe sets. 
 
Nuclease accessibility assay 
Nuclease  accessibility  assay  was  performed  with  EpiQ  chromatin  analysis  kit  (Bio-Rad,  172-5400) 
following instructures from the manufacturer. In brief, leukemia cells with or without Af10 deletion were 
processed in two treatment groups: undigested and digested. The undigested group was not digested with 
the EpiQ nuclease, the digested group was treated with limited EpiQ nuclease digestion according to the 
kit instruction. The genomic DNA samples for both groups were isolated and subjected to quantitative 
PCR.  Primers  for  qPCR  are:  Hoxa7  (forward:  TTTCCGGGGCAATTCCATTGTGAAG;  reverse: 
CAGATCCCGCGGCTTCACCTTTCTA); Hoxa9 (forward: CAATGTCCAGTGTTCCTCCCGGGTTA; 
reverse: TTGCTGAGGGGTCACCTCGCCTAGT); Hoxa10 (forward: CGGCCTTTGAGCCATAGGTG 
TCAGG;  reverse:  TGGCGAAGGGAGCAGATAGCCCTTT);  Hoxa11  (forward: 
TTACACCGGCGATTACGTGCTTTCG;  reverse:  TCCACTGCAGCTGCCTCTTTGAAGC);  Hoxa13 
(forward: GGGAGCTAGAGCTGGCGCAGAGGAC; reverse: AGCCGCATGGAGAAGACCCCAGTG; 
Meis1 (forward: ATTTGTGTGCATGTGCCCTGGGTGT; reverse: CGCCGTGCGTGTGTAAAGTGTG 
TGT); Gapdh (forward: CCAGCACAGATGGAGCGGAAAGAGG; reverse: CCTAGTCCCTGCGCCG 
GTACATTCA);  -Actin  (forward:  CCACAAGGGCGGAGGCTATTCCTGT;  reverse: 
ACAGCGGCCACTCGAGCCATAAAAG ); Hoxb1 (forward: TCGCTCTCAGATGGATGGGCTCAG; 
reverse: TGGGGGAGACACCCTCTTGCCCTAC). qPCR results for all samples were normalized to an 
internal control, a fragment of an unexpressed gene Rhodopsin according to the kid instruction. Nuclease 
accessibility index was calculated as the ratio between the undigested sample and the digested sample at 
the same time point.   
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Chapter 6  
 
Conclusions and Perspectives  
 
97 
 
 
 
The DOT1L-AF10 complex is a promising therapeutic target in MLL-rearranged leukemia  
Rearrangements of the Mixed-Lineage Leukemia (MLL) gene are found in > 70% of infant leukemia, ~ 
10%  of  adult  de  novo  acute  myeloid  leukemia,  and  many  cases  of  secondary  acute  leukemias.  The 
diversity of MLL fusion partners poses a challenge to developing a unified mechanistic model for MLL-
rearranged leukemias. However, gene expression signatures of MLL rearranged leukemias are remarkably 
similar, with high expression of MLL targets such as HOXA loci and MEIS1, which can be reliably used 
to distinguish leukemias with MLL rearrangements from other subtypes. We showed that MLL rearranged 
leukemias with nuclear fusion partners and with cytoplasmic fusion partners both have aberrantly high 
methylation at histone H3K79 in MLL target genes. This epigenetic lesion may be involved in driving the 
gene expression signatures in MLL rearranged leukemias. We further demonstrated that Dot1l is essential 
for the leukemogenesis of several MLL- and CALM-fusion driven leukemias with dismal outcome, such 
as MLL-AF10, MLL-AF6, and CALM-AF10. Our results with genetic and pharmacological approaches 
support the notion of inhibiting H3K79 methylation by DOT1L as a new therapeutic strategy for MLL-
rearranged leukemia. 
 
We  further  showed  that  Af10,  a  key  component  of  Dot1l  complex,  is  required  for  global  H3K79 
dimethylation  but  not  H3K79  monomethylation.  Using  an  Af10
OM-LZ  knockout  mouse  model,  we 
demonstrated  that  genetic  disruption  of  Af10-Dot1l  interaction  abrogated  in  vitro  bone  marrow 
transformation by MLL-AF9 and MLL-AF6, and resulted in prolonged survival of mice injected with 
Af10
OM-LZ deleted MLL-AF9 leukemic cells compared to mice injected with Af10
OM-LZ floxed MLL-AF9 
leukemic cells. Nuclease accessibility assay and microarray revealed that deletion of Af10
OM-LZ led to 
chromatin  compaction  and  downregulation  of  gene  expression  in  highly  selective  MLL  target  loci, 
without affecting the chromatin structure and gene expression in the majority of the genome. Our results 
reveal the AF10-DOT1L interaction as an attractive therapeutic target in MLL-rearranged leukemias.  
 
98 
 
 
Identifying new dependence in genetically-defined cancer cells for the design of targeted therapy 
The term “targeted cancer therapy” describes various approaches that aim to block the growth of cancer 
cells based on specific molecular characteristics of the cancer, rather than by general inhibition of cell 
division. One of the first definitive experiments that showed that targeted therapy would reverse the 
malignant phenotype of tumor cells was the treatment of Human Epidermal Growth Factor Receptor2 
(HER2)-transformed cells with anti-HER2 monoclonal antibody in vitro and in vivo in 1985 (103). Since 
then, more and more targeted therapies have been validated by pre-clinical experiments and been used in 
clinical  applications,  including  Tyrosine  kinase  inhibitor  Gleevec  for  BCR-ABL  rearranged  chronic 
myeloid leukemia (1) and BRAF inhibitor Zelboraf for BRAF mutated melanoma (104), both of which 
are examples of successful targeted cancer therapy.  
 
Targeted cancer therapies benefit patients by increasing “therapeutic index”, or to put it another way, by 
maximizing therapeutic efficacy and minimizing toxicity. One critical first step in the design of targeted 
cancer therapy is the identification of molecular “Achilles’ Heels” of genetically-defined cancer cells. 
Recent cancer genomic discovery efforts, such as whole genome sequencing, continue to reveal genetic 
mutations in various types of human cancer. Some of the mutations are driver mutations, which actively 
drive oncogenesis by promoting cell division and/or blocking cell differentiation and cell death, while 
some of the mutations are passenger mutations, which are not critical to the development of cancer but 
may be involved in the progression of the specific disease. Previously, the effort of discovering targets 
has  been  focused  on  identifying  oncogene  mutations  that  drive  the  oncogenesis  directly.  Targeted 
therapies  have  been  established  for  BRAF  mutated  melanoma,  BCR-ABL  rearranged  CML,  HER2 
positive breast cancer by inhibiting the hyperactive oncogenic proteins that turn on cell division through 
signaling pathways. This type of targeted therapy usually possesses an enormous therapeutic window 
because it inhibits the oncogene on which cancer cells are dependent but normal cells are not. However,  
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this type of targeted therapy design sometimes faces limitations regarding the druggability of the specific 
oncogene and the issue of drug resistance.  
 
Interestingly,  our  research  revealed  that  some  non-oncogenes  also  have  the  potential  to  be  great 
therapeutic targets for genotype-specific cancers. Normal cells are not affected by the suppression of the 
non-oncogenes due to functional redundancy of homologous genes or compensation by other pathways. 
However, specific oncogenic mutation may depend on these non-oncogenes to drive cancer cell division 
or to turn off cancer cell differentiation and apoptosis. In this case, the oncogene mutation creates a new 
co-dependence on specific non-oncogenes in the development of cancer. Targeting these special non-
oncogenes will kill the genotype-specific cancer cells while sparing normal cells.  
 
MLL-rearranged leukemias are driven by the oncogenic MLL-fusion proteins, which are not ideal targets 
for drug development due to the diversity of MLL fusion partners and the importance of MLL in normal 
cells. Our results demonstrated that MLL-rearranged leukemias depend on the function of DOT1L, which 
can serve as an alternative drug target. Based on the cancer genome sequencing data, the gene encoding 
DOT1L is relatively quiet. Although not an oncoprotein, DOT1L is specifically hijacked to MLL-fusion 
targets in MLL-rearranged leukemic cells and drives the expression of the oncogenic target genes. Loss of 
DOT1L selectively killed MLL-fusion transformed bone marrow cells but had no effect on HoxA9/Meis1 
transformed cells. In addition, genetic deletion of DOT1L led to a selective silencing of MLL-fusion 
target genes without inhibiting general transcription.  Furthermore, preclinical studies have shown that 
DOT1L inhibitor has a great efficacy in treating MLL-rearranged leukemia and it is well tolerated in mice 
(105), suggesting a huge therapeutic window of DOT1L inhibitors for patients with MLL-rearranged 
leukemias.  
  
 
100 
 
Recently,  William  Hahn’s  group  published  another  study  describing  the  co-dependence  between  the 
oncogene KRAS and a non-oncogene TBK1 (106). KRAS mutation is a common driver mutation in 
pancreatic cancer and is very difficult to target because of high gene mutation rate and frequent drug 
resistance. TBK1 is an essential KRAS partner. It is a non-oncogene and is dispensable for normal cells. 
Through  genome-wide  shRNA  screen,  Hahn’s  group  discovered  that  KRAS-mutated  cancers  are 
specifically  sensitive  to  the  suppression  of  TBK1,  suggesting  TBK1  as  a  new  therapeutic  target  for 
KRAS-mutated cancers. Together, the two studies support the use of non-oncogene as targets for patient-
specific therapy.  
 
The idea of co-dependence between specific oncogene and non-oncogene may open up a much broader 
class of protein targets for new therapy. As long as the efficacy and toxicity is well monitored, not only 
oncogenes can serve as drug targets, non-oncogenes can also serve as therapy targets for cancer based on 
patient-specific molecular features. In the near future, the joint efforts in high-throughput sequencing, 
chemical genomic screening and bioinformatics will build connection between genotype-specific cancer 
and potential targets and contribute to the development of personalized targeted cancer therapy.  
 
H3K79  methylation  inhibitors  show  promise  in  personalized  medicine  for  patients  with  MLL-
rearranged leukemia. 
The  preclinical  result  of  optimized  DOT1L  inhibitor  showed  promise  for  personalized  medicine  for 
patients with MLL-rearranged leukemia (105). Based on this, the first-in-human clinical trial of DOT1L 
inhibitor is ongoing. Although we believe that targeting DOT1L enzymatic activity domain will be an 
important  therapeutic  approach  in  MLL-rearranged  leukemia,  single  agent  therapy  is  virtually  never 
curative. Our results support an alternative approach to inhibit H3K79 methylation. Besides targeting the 
enzymatic active domain of DOT1L, targeting the protein-protein interaction between DOT1L and the  
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OM-LZ  domain  of  AF10  can  also  suppress  H3K79  dimethylation  and  inhibit  the  growth  of  MLL-
rearranged  leukemia.  With  advances  in  pharmacology  and  biochemistry,  designing  small-molecule 
inhibitors to target protein-protein interaction has now become very feasible. An epigenetic drug JQ1, 
which targets the interaction between bromodomain and acetylated histone H4 thus inhibiting c-Myc 
activation, has proven effective in treating human multiple myeloma in preclinical animal studies (107). 
Given  the  involvement  of  aberrant  H3K79  dimethylation  in  MLL-rearranged  leukemia  and  the 
requirement  of  AF10-DOT1L  interaction  for  H3K79  dimethylation,  I  envision  that  small-molecule 
inhibitors targeting AF10-DOT1L interaction combined with the DOT1L enzymatic domain inhibitor or 
with differentiating and/or apoptosis agents may yield better therapy.  
 
In the past decade, the successful use of epigenetic drugs in clinical and preclinical studies has lighted up 
cancer research.  In this thesis, I focused on one type of epigenetics-- chromatin modifications. However 
based on a broad definition of epigenetics, every program that maintain a heritable change of cell state 
without  altering  DNA  sequence  can  be  called  as  epigenetics.  It  includes  DNA  methylation,  histone 
modification,  small  RNA-mediated  silencing,  and  many  other  mechanisms  that  we  have  not  yet 
understood clearly. The scientific curiosity and the hope of benefiting patients will continue to drive me 
and millions of other scientists to study cancer epigenetics and targeted therapy. 
 
Concluding remarks 
To conclude, our studies presented here contribute to a growing body of cancer epigenetic studies. Cancer, 
as a cell state, is influenced by the epigenetic program that determines how chromatins are packaged and 
how  the  genome  gets  expressed.  Growing  evidence  supports  that  targeting epigenetic  modifiers  may 
correct the deregulated epigenetic program in cancer, and set the cell state back to normal. We are glad to 
see  the  first-in-human  clinical  trial  of  DOT1L  inhibitor  is  underway.  It  is  our  hope  that  continued  
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advances in our understanding of MLL leukemia mechanism and in the development of more effective 
epigenetic drugs will eventually make an impact in the treatment of this dismal disease.    
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